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Homeostatic regulation of energy balance is a precise tool concerned with 
maintaining a stable balance between energy intake and expenditure. Failure in the 
regulation of this physiological process gives rise to some disorders that are now 
considered public health problems with their reported increase in prevalence rate such 
as obesity and cachexia. Obesity is caused by a chronic rise in energy consumption 
while cachexia results from a long-standing increase expended energy. Brown adipose 
tissue (BAT) thermogenesis is a crucial component of the energy balance equation. 
Recently, the hypothalamus and in particular, the ventromedial nucleus of the 
hypothalamus (VMH), vital role in the regulation of BAT activity has emerged. The 
hypothalamic AMP-activated protein kinase (AMPK), a sensor of energy levels, not 
only has a pivotal role in the regulation of both cellular and whole body energy 
balance but also is crucial in regulating BAT thermogenesis through the sympathetic 
nervous system (SNS).  
The impact of sexual dimorphism on energy homeostasis and fat distribution is 
well established. Also, the influence of sex steroids on energy balance has been 
reported. Here, we demonstrate that estrogens and androgens have a major role in the 
modulation of energy balance through central actions. Central estradiol (E2) treatment 
inhibits AMPK in the VMH, leading to activation of thermogenesis in BAT in a 
feeding-independent manner. Moreover, fluctuations in E2 levels during estrous cycle 
also modulate this integrated physiological network. On the other hand, 
dihydrotestosterone (DHT)-treatment inhibited BAT thermogenesis so that the central 
effects of androgens on energy expenditure cannot be attributed to aromatization. 
Notably, central DHT-treatment demonstrated the ability to modulate the lean mass. 
Overall, these findings showed that E2 and DHT regulation of the VMH AMPK-SNS-
BAT axis is an essential determinant of energy balance and suggest potential targets 









La regulación homeostática del balance energético es una precisa herramienta que se 
ocupa de mantener un equilibrio estable entre la ingesta y el gasto energético. Cualquier 
desequilibrio en la regulación de este proceso fisiológico dará lugar a algunos trastornos que 
son considerados hoy en día un problema de salud pública con una prevalencia creciente tal 
como la obesidad y la caquexia. La obesidad está causada por un aumento crónico en 
consumo de energía y la caquexia es el resultado de un aumento mantenido durante mucho 
tiempo del gasto energético. La termogénesis del tejido adiposo marrón (Brown adipose 
tissue; BAT) es un componente crucial en la ecuación del balance energético. Recientemente, 
el hipotálamo y en particular, el núcleo ventromedial del hipotálamo (ventromedial nucleus 
of the hypothalamus; VMH) ha surgido como principal regulador de la actividad del BAT. La 
proteína quinasa hipotalámica activada por AMP (AMP-activated protein kinase; AMPK), un 
sensor de los niveles de energía, no sólo tiene un papel fundamental en la regulación del 
balance energético celular y de todo el cuerpo, sino que también es crucial en la regulación de 
la termogénesis del BAT a través del sistema nervioso simpático (sympathetic nervous 
system; SNS).  
El impacto del dimorfismo sexual en la homeostasis energética y la distribución de la 
grasa está bien establecido. A su vez, también se ha reportado la influencia de los esteroides 
sexuales sobre el balance energético. Aquí, se demuestra que los estrógenos y los andrógenos 
tienen un papel importante en la modulación del balance energético a través de acciones 
centrales. El tratamiento central con estradiol (estradiol; E2) inhibe la AMPK en VMH, 
conduciendo a la activación de la termogénesis en el BAT de manera independiente a la 
ingesta. Además, las fluctuaciones en los niveles de E2 durante el ciclo estral también 
modulan esta red fisiológica. Por otro lado, el tratamiento central con dihidrotestosterona 
(Dihydrotestosterone; DHT) inhibe la termogénesis en BAT de manera que los efectos 
centrales de los andrógenos sobre el gasto energético no se pueden atribuir a la 
aromatización. De manera notable, el tratamiento central con DHT demostró la capacidad de 
modular la masa magra. En general, estos resultados demuestran que la regulación del E2 y la 
DHT sobre el eje AMPK VMH-SNS-BAT es un determinante esencial del balance energético 








A regulación hemostática do balance enerxético é unha ferramenta que se encarga de 
manter un equilibrio estable entre a inxesta é o gasto enerxético. Calquera desequilibrio na 
regulación deste proceso vai levar a trastornos fisiolóxicos que se consideran hoxe un 
problema de saúde pública co aumento da prevalecía de obesidade e caquexia. A obesidade é 
causada por un aumento no consumo de enerxía crónica e a caquexia é o resultado dun 
aumento do gasto de enerxía a longo mantida. A termoxéneses do tecido adiposo marrón 
(Brown adipose tissue; BAT) é un compoñente crucial na ecuación do balance enerxético. 
Recentemente o hipotálamo e, en particular o núcleo Ventromedial do hipotálamo 
(ventromedial nucleus of the hypothalamus; VMH), ten emerxido como o principal regulador 
da actividade de BAT. A proteína hipotalámica quinasa AMP-activada (AMP-activated 
protein kinase; AMPK), un sensor dos niveis de enerxía, non só ten un papel fundamental na 
regulación do balance enerxético celular e todo o corpo, senón que tamén é crucial na 
regulación da termoxénese BAT a través do sistema nervioso simpático (sympathetic nervous 
system; SNS). 
O impacto de dimorfismo sexual na homeostase enerxética e  na distribución de graxa 
está ben establecida. Pola súa banda, tamén foi investigada a influencia dos esteroides sexuais 
sobre o equilibrio de enerxía. Aquí, móstrase que os estróxenos e andróxenos teñen un papel 
importante na modulación do balance enerxético, a través de accións centrais. O tratamento 
central con estradiol (estradiol; E2) inhibe a AMPK no VMH, conducindo á activación da 
termoxéneses no BAT independentemente da inxesta. Ademais, as flutuacións nos niveis de 
E2 durante o ciclo estral tamén modulan esta rede fisiolóxica. Ademais, o tratamento central 
con dihidrotestosterona (dihydrotestosterone; DHT) inhibe termoxénese no BAT de xeito que 
os efectos centrais dos andróxenos sobre o gasto enerxético non poden ser atribuídos a 
aromatización. Notablemente, o tratamento central con DHT demostrou a capacidade para 
modular a masa magra. En xeral, estes resultados demostran que a regulación do E2 e a DHT 
no eixe AMPK VMH-SNS-BAT é un determinante fundamental do balance enerxético e 
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1. Obesity epidemic and associated diseases 
Obesity has emerged as an issue of considerable concern. The American 
Medical Association (AMA) in 2013 has declared obesity as a disease (Atkinson, 
2014). Obesity occurs due to a chronic imbalance between energy intake and energy 
expenditure; energy utilized exceeds what is expended causing overgrowth of the 
adipose tissue to a level that adversely affects the state of health (Sanchez-Gurmaches 
and Guertin, 2014b). Since measuring the fat mass directly is technically difficult, the 
Body mass index (BMI; an individual's weight divided by his height in kg/m2) has 
alternatively been used as an indicator of adiposity (Farooqi and O'Rahilly, 2005). The 
use of BMI has its limitations; it is a measure of weight, not fat content (Atkinson, 
2014). The world health organization (WHO) has defined obese persons as those who 
have a BMI over 30 kg/m2 (van der Klaauw and Farooqi, 2015) while those with BMI 
over 25 are considered to be suffering from overweight (Farooqi and O'Rahilly, 2005).  
Obesity is linked to comorbidities including insulin resistance, type 2 diabetes 
(T2D), cardiovascular disease, cancer, a range of other disorders collectively known 
as the metabolic syndrome (van der Klaauw and Farooqi, 2015). Also, sleep apnea, 
inflammation, gall bladder disease, breathlessness, gestational diabetes mellitus, and 
fatty liver disease (Sturm, 2002). Furthermore, high risk of coronary heart disease, 
back problems, gout, stroke, cancer, cataracts, stroke, osteoarthritis and impaired 
fertility were reported (Calkins and Devaskar, 2011). These bulk of diseases makes 
that the medical costs associated with obesity add more than $200 billion annually in 
the United States alone (Heindel et al., 2015). In 2010, estimated mortality from 
obesity and overweight was nearly 3.4 million per year (Lim et al., 2012b). 
Recently, obesity prevalence level has been elevated in both developed and 
developing countries (Hebert et al., 2013). A dramatic doubling in the global 
prevalence of obesity over the past decades from 6.4% in 1980 to 12.0% in 2008 has 
also been reported (Stevens et al., 2012). In 2014, the WHO showed that the region of 
the Americas have the highest prevalence of obesity (27% obese) while the South-East 
Asia region was the lowest (5% obese) (WHO, 2014). Also, differences in prevalence 




obese (WHO, 2014). Interestingly, in the European and Eastern Mediterranean regions 
and region of the Americas roughly 25% of women are obese (Figure 1). 
Obesity is now known to have multiple etiologies and predisposing factors. 
Both the changes in our environment, as well as genetic predisposition constitute the 
major predisposing factors. Changes in our daily lifestyle have stood for promoting 
obesity; the availability of intense energy palatable food with less physical activity. 
Also, individuals appear to be genetically more vulnerable to weight gain than others. 
However, body fat growth and distribution patterns vary according to the gender 
difference (Geer and Shen, 2009). Women show higher tendencies toward adiposity 
than men do, men usually accumulate fat centrally while women tend to have more fat 
on the lower body regions (Geer and Shen, 2009). 
All current approaches for treating obesity either with dieting, exercising or 
changing the lifestyle have proven to be a failure rendering obesity with a temporary 
relief and no cure (Atkinson, 2014). Developing more efficient anti-obesity drugs is 
shown itself to be the future of research in this field that should focus on a better 
understanding of the underlying etiologies and mechanisms of obesity. Recent studies 
on obesity have drawn much attention toward the impact of the regulatory 
mechanisms of energy balance on the quality of human life both at individual and 
community levels. The fact that women are more susceptible to obesity than men has 
included the sexual dimorphism in the equation. The governing factors of this 
dimorphism remain not fully understood. Thus, the involvement of sex steroid 






Figure 1: Global prevalence of obesity: (A) among men and (B) in women.  The age range for 





2. Cachexia and wasting in chronic diseases 
Cachexia is a complex metabolic syndrome resulting from a long-standing 
imbalance between energy intake and expenditure where dietary energy intake is 
exceeded by the energy expenditure (Evans et al., 2008). Patients suffering from 
cachexia, usually lose weight mainly muscle with or without loss of fat mass without 
actively trying (Evans et al., 2008). They also suffer from muscle atrophy associated 
with weakness, fatigue as well as reduced appetite. Cachexic patients are those who 
lose more than 5% of their body weight in one year or less (Yoshida and Delafontaine, 
2015). It is usually linked to underlying chronic illness such as chronic obstructive 
pulmonary disease, chronic kidney disease (CKD), congestive heart failure (CHF), 
and cancer. While the worldwide estimation of cachexia burden remains inconclusive, 
some studies show that its prevalence ranges from 5–15 % in end-stage chronic heart 
failure to 50–80 % in case of advanced cancer (Arthur et al., 2014; von Haehling and 
Anker, 2010).   
Also, Cachexia is proven to be a multifactorial syndrome that cannot be 
entirely reversed by dietary supplementation. In cachexia conditions, the level of 
muscle protein degradation, myofibrillar protein, exceeds its synthesis, this imbalance 
results in rapid loss of muscle mass (Yoshida and Delafontaine, 2015). The biggest 
problem of cachexia is that it can significantly reduce the quality of life or even 
terminate it; weight loss and decreased muscle mass are associated with increased 
mortality (Lok, 2015). Thus, cachexia is a significant public health issue, and the 
development of interventions to block or attenuate it would have notable therapeutic 
benefits valuable in patients suffering from a variety of chronic diseases. Despite the 





Figure 2: Cachexia and muscle wasting involve multiple organs alterations. Modified from 
(Argiles et al., 2014).  
3. Homeostatic regulation of energy balance 
Living organisms always strive to maintain their internal environment and 
systems in a state of equilibrium i.e. homeostasis to survive. Energy balance is no 
exception; our body struggles to provide a stable balance between energy consumed 
and expended. The peripheral organs and tissues including the gut, white adipose 
tissue (WAT), gonads, muscles, and thyroid continuously supply signals about the 
metabolic and nutritional status to the CNS. The CNS then integrates them and 
provoke the proper response that allows efficient energy homeostasis (Flier, 2004; 
Fruhbeck and Gomez-Ambrosi, 2003; Lopez et al., 2007b; Medina-Gomez and Vidal-
Puig, 2005; Wren and Bloom, 2007). This complex homeostatic mechanism can be 





Figure 3. The homeostatic pathways of energy balance. Modified from (Gale et al., 2004). 
3.1.  Peripheral signals: 
Different peripheral signals are implicated in the regulation of energy balance 
including hormonal signals; the gut hormones such as cholecystokinin (CCK), peptide 
YY (PYY), and glucagon-like peptide (GLP-1), mechanical signals; gastric distension, 
chemical signals: ingested food components and nerve signal; vagal afferent 
stimulation. All of these signals collaborate on maintaining the CNS informed about 
the changes in hunger/satiety condition as well as the status of the different energy 
stores. Peripheral signals can be classed as long-acting adiposity signals and short-
acting gastrointestinal factors. Though, some evidence on appetite-regulating 
hormones including ghrelin and PYY showed that they are involved in the regulation 
of appetite on both short and long-term basis rendering the margin between both 




The long-acting signals such as insulin and leptin are secreted in proportion to the 
levels of energy stored as fat and regulate body weight and fat stores over the long 
term. Short-acting gastrointestinal signals including gut hormones suppress food 
intake through the sensation of fullness promoting meal termination and satiation 
(Wren and Bloom, 2007).  
3.1.1. Adipose tissue signals (Adipokines). 
Since Zhang et al. discovered that adipocytes are capable of secreting a 
hormone called leptin (Zhang et al., 1994). There has been a complete change in the 
perception of WAT, not only energy stores but also an endocrine organ, various 
adipokines, adipocytes derived proteins, including adiponectin,  has been identified 
(Bouloumie et al., 2005). Adipokines have pleiotropic activity, acting both locally and 
systemically, their effect involves the brain, and sympathetic nervous system (SNS), 
skeletal muscle, immune system, adrenal cortex. They are involved in the regulation 
of appetite, feeding behaviour, fat metabolism, and insulin sensitivity (Trayhurn et al., 
2006). The synthesis and secretion of adipokines are an active process; their level 
depends on the quantity and distribution of fat mass as described in both human and 
animal models (Berryman et al., 2004; Staiger et al., 2003; Vidal, 2001). For instance,  
leptin and adiponectin levels correlate with the degree of adiposity, leptin positively 







Table 1. Metabolic functions of key adipokines.  
 
3.1.2. Gastrointestinal signals 
The gastrointestinal tract secretes multiple peptides that have been implicated 
in energy balance regulation. The main peptide signals are ghrelin secreted from 
gastric mucosa, CCK from duodenum and jejunum as well as PYY and GLP-1 from 
the distal small intestine and colon. In addition to these, oxyntomodulin, a cleavage 
product of proglucagon is known to be secreted in response to food and reduce gastric 
motility and secretion as well as food intake (Cohen et al., 2003; Dakin et al., 2004; 
Wynne et al., 2005). Pancreatic polypeptide (PP) and amylin secreted from the 
endocrine pancreas have also been involved in the control of food intake. PP decreases 
food intake and may delay gastric emptying and enhances energy expenditure 




participates in the control of glucose homeostasis and can also suppress food intake, at 
least at high levels (Morley and Flood, 1991; Roth et al., 2007). 
 
Table 2. Gastrointestinal peptides and energy balance 
3.2. Central regulation of energy balance 
Neuronal circuits directly or indirectly regulate all physiological activities. 
Experimental studies pointed out that organs involved in energy homeostasis, such as 
liver, muscle, adipose tissue, gut or the pancreas, are under direct control of the CNS 
(Kleinridders et al., 2009; Plum et al., 2007; Pocai et al., 2005). The emerging facts 
about obesity, diabetes, and other metabolic comorbidities epidemics has directed 
considerable efforts to understand the exact mechanisms involved in both the 
influence of the different homeostatic signals as well as the central responses to 
regulate feeding and glucose metabolism. Experimental evidence vastly points out to 
the pivotal role of the hypothalamus in energy homeostasis regulation (Dieguez et al., 







3.2.1. Hypothalamic homeostatic regulation of energy balance 
The hypothalamus is considered the primary regulator of food intake and 
energy homeostasis. It consists of a collection of distinct hypothalamic nuclei such as 
ARC, VMH, LHA, DMH, and the PVH.  
 
Figure 4. Hypothalamic regulation of energy balance (Lopez et al., 2013). 
3.2.1.1.  Arcuate nucleus (ARC)  
The ARC is a key site in the control of energy homeostasis. Its anatomical 
location, ventral to the VMH on both sides of the third ventricle immediately adjacent 
to the median eminence (ME), is advantageous for sensing the hormonal and chemical 
changes in the bloodstream through the blood–brain barrier (BBB) (Broadwell and 
Brightman, 1976). The ARC contain two key neuronal populations; a) Orexigenic 
neurons: express neuropeptide Y (NPY) and agouti-related peptide (AgRP), b) 
Anorexigenic neurons: express the cocaine and amphetamine regulated transcript 
(CART) and proopiomelanocortin (POMC) that is a precursor of α-melanocyte 
stimulating hormone (α-MSH).  
POMC is the key element of the central melanocortin system; that is involved 




peripheral signals consists of these two neuronal populations and the downstream 
target neurons expressing the melanocortin receptor 3 (MC3R) and the melanocortin 
receptor 4 (MC4R).  
NPY, a 36 amino acid peptide (Tatemoto, 1982), is widely expressed in the 
CNS predominantly in the ARC (Gehlert et al., 1987). NPY expression and release 
vary depending on the changes in energy status, being decreased under feeding 
conditions and increased under fasting conditions (Beck et al., 1990). NPY is a 
powerful central appetite-stimulant and acts upon its receptors, Y1, Y2, Y4, Y5, but 
exerts its orexigenic effect predominantly via the Y1 and Y5 receptors (Nguyen et al., 
2012; Sohn et al., 2013). ICV administration of NPY stimulated food intake in a dose-
dependent manner (Clark et al., 1985; Levine and Morley, 1984). Chronic 
administration of NPY produced a sustained hyperphagic effect and increased body 
weight (Beck et al., 1992; Zarjevski et al., 1993). 
Most of the NPY neurons also co-express AgRP, also, an orexigenic 
neuropeptide expressed in the ARC (Broberger et al., 1998; Campbell et al., 2001). 
AgRP is the endogenous antagonist of the melanocortin receptors (Cone, 2005; Flier, 
2006; Williams and Schwartz, 2005). Of particular convincing nature was genetic 
overexpression or central administration of AgRP studies showing hyperphagia and 
reduced energy expenditure resulting in obesity (Graham et al., 1997; Ollmann et al., 
1997; Small et al., 2003). The orexigenic effect of central AgRP administration lasted 
for few days (Hagan et al., 2000). Conversely, Agrp and Npy knockout (KO) mice 
showed no changes in feeding or body weight (Corander et al., 2011). However, 
ablation studies of AgRP neurons in adults results in hyperphagia, weight loss, and 
starvation (Gropp et al., 2005; Luquet et al., 2005). In contrast, neonatal loss of AgRP 
or AgRP neurons does not produce any effects regarding food intake or body weight 
(Luquet et al., 2005). 
CART is co-expressed by the POMC neurons in the ARC (Elias et al., 1998). 
CART is involved in the regulation of food intake, maintenance of body weight, 
reward and addiction, stress response, psychostimulant effects and endocrine 
functions (Lau and Herzog, 2014; Rogge et al., 2008; Subhedar et al., 2014). Fasting 




enhances BAT thermogenesis of (Kotz et al., 2000). Central administration of CART 
decreases food intake, whereas that of CART antiserum increases food intake 
(Kristensen et al., 1998). Also, no changes in food intake or body weight were noticed 
in Cart-pt-deficient mice supplied with a standard diet, although high-fat diet (HFD) 
induced obesity was used (Asnicar et al., 2001). The role of CART may be more 
complicated than initially expected since injections of CART in some specific nuclei 
may increase food intake (Abbott et al., 2001; Kong and Carter, 2003). 
POMC neurons are laterally located in the ARC (Mizuno et al., 1998). 
Cleavage of POMC by endoproteases yields bioactive peptides including α -MSH, 
that has anorexigenic effects by binding to MC3R and MC4R thus essential for 
normal energy homeostasis (Mercer et al., 2013; Schwartz et al., 2000). Feeding 
augment the expression of POMC as well as α -MSH while fasting reduces them 
(Schwartz et al., 1997). Central administration of α -MSH  reduced feeding and 
caused weight loss (Wirth et al., 2001). Obese mice exhibit decreased hypothalamic 
POMC mRNA expression (Mizuno et al., 1998). Also, animal models lacking POMC 
developed hyperphagia and obesity (Coll et al., 2004). Anti-obesity effect of the α-
MSH has been reported in genetically manipulated POMC genes so that α-MSH is 
overexpressed, also reported in rat models fed on HFD (Lee et al., 2007; Mizuno et 
al., 2003; Savontaus et al., 2004). Human studies have reported that POMC gene 





Figure 5. AgRP/NPY and POMC/CART neurons of the ARC. Modified From (Barsh and 
Schwartz, 2002). 
3.2.1.2. Paraventricular nucleus (PVH) 
The PVH is located on either side of the superior part of the third ventricle in 
the anterior hypothalamus. Its magnocellular neurosecretory neurons project directly 
to the posterior pituitary where they release oxytocin or vasopressin into the general 
circulation (Russell et al., 1988). Also, The parvocellular neurosecretory neurons 
project to the ME and release CRH, TRH, growth hormone-releasing hormone 
(GHRH), and dopamine into the portal blood vessels of the anterior pituitary 
(Whitnall, 1993). The PVH also has neurons that expressed neuropeptides such as 
CART, (Hillebrand et al., 2002; Leibowitz and Wortley, 2004). The PVH expresses 
high levels of MC3R/MC4R. Regarding the energy homeostasis, the PVH is 
considered a valuable integration center as it receives several afferent inputs such as 
those from the AgRP and POMC neurons of the ARC or even from nucleus tractus 




the ARC innervate TRH neurons in the PVH and inhibit pro-TRH gene expression, 
whereas α-MSH/POMC projections stimulate TRH (Fekete et al., 2000; Fekete et al., 
2002; Legradi and Lechan, 1999). Specific nucleus administration of some 
neuropeptides such as NPY, AgRP, and a-MSH has proven its involvement in the 
regulation of food intake (Kim et al., 2000; Stanley et al., 1986).  
3.2.1.3. Lateral hypothalamus area (LHA) 
The LH extends rostrally from the mesencephalic tegmentum to the lateral 
preoptic area in dorsal and lateral aspect to VMH (de Lecea et al., 1998). It contains 
sparsely distributed subpopulation of neurons expressing melanin-concentrating 
hormone (MCH) and orexins (orexin A and B) (de Lecea et al., 1998; Ferno et al., 
2015; Lopez et al., 2010a; Sakurai et al., 1998) thus it is involved in the mediation of 
orexigenic responses. Orexin neurons produce orexin A and orexin B from 
preproorexin, with an increase in expression under fasting conditions (Sakurai et al., 
1998). Central administration of orexins to rodents elicited hyperphagia (Dube et al., 
1999; Lopez et al., 2002; Sakurai et al., 1998). Orexin neurons have extensive 
communication with other brain centers, it receives many projections from 
NPY/AgRP and α-MSH/POMC neurons from the ARC, also from LHA, PVH, and 
NTS (de Lecea et al., 1998; Peyron et al., 1998). Orexins have been reported to play a 
significant role in sleep regulation; orexin deficiency causes a sleep disorder termed 
narcolepsy (Chemelli et al., 1999; Hara et al., 2001). Recently, a role for orexin in the 
control of BAT thermogenesis in the rostral raphe pallidus (rRPa) was reported 
(Tupone et al., 2011). Orexin null mice suffered from a failure of BAT thermogenesis 
owing to the inability to differentiate in brown pre-adipocytes (Sellayah et al., 2011). 
MCH expression is enhanced by fasting while its ICV administration or genetic 
overexpression causes hyperphagia (Ludwig et al., 2001; Qu et al., 1996). Also, 
central MCH directly controls hepatic and adipocyte metabolism through different 
pathways (Imbernon et al., 2013). 
3.2.1.4. Dorsomedial nucleus (DMH) 
The DMH receives projections from the ARC NPY and α-MSH/POMC 
neuronal terminals (Broberger et al., 1998), whereas it sends projections to 




Electrolytic destruction of the DMH causes hyperphagia and obesity (Bernardis and 
Bellinger, 1987). It has been noted that the DMH expresses neuropeptides such as 
NPY and CRH as well as receptors for other peptides involved in the control of 
appetite and energy balance (Chan et al., 1996; Kamegai et al., 1996). NPY gene 
expression is increased in the DMH in case of diet-induced obesity and genetic obese 
mice (Elmquist et al., 1998; Li et al., 1998), as well as during pregnancy and lactating 
periods. The DMH is also involved in the regulation of brown adipose tissue (BAT) 
thermogenesis (Chao et al., 2011).  
3.2.1.5. Ventromedial nucleus (VMH) 
The VMH of the hypothalamus, located adjacent to the ARC, receives 
NPY/AgRP and POMC/CART projections from the ARC (Koylu et al., 1997; 
Kristensen et al., 1998). Also, it sends efferent projections to the DMH, PVH, ARC 
and brain stem regions such as NTS (Cheung et al., 2013). The neurons in the VMH 
have long been hypothesized to play a major role in metabolic regulation since 
bilateral VMH lesions cause hyperphagia and obesity (Weingarten and Powley, 1980). 
Brain-derived neurotropic factor (BDNF) is highly expressed in the VMH, and central 
or peripheral administration of BDNF reduces feeding and causes body weight loss 
(Lapchak and Hefti, 1992; Pelleymounter et al., 1995) through MC4R signalling (Xu 
et al., 2003). Also both humans and mice studies have demonstrated that lacking 
BDNF or its receptor leads to hyperphagia and obesity (Lyons et al., 1999; Yeo et al., 
2004). Also, the identification of the steroidogenic factor 1 (SF1) in the VMH (Davis 
et al., 2004; Parker et al., 2002) was valuable in production of conditional KO mice 
proving the critical role of VMH in energy homeostasis (Bingham et al., 2008; Kim et 
al., 2011; Zhang et al., 2008). Recent findings have promoted the role for AMPK in 
the VMH on the regulation of thermogenesis (Lopez et al., 2010b; Martinez de 
Morentin et al., 2012; Whittle et al., 2012). 
3.3. Energy expenditure (EE) 
Maintaining relatively stable body weight is an active process that includes a 
balance between food intake and energy expenditure. Under normal physiological 
conditions, food is used to provide energy that is usually used in resting metabolic rate 




energy expenditure. RMR refers to the amount of energy the body uses at rest to 
maintain the basic cellular metabolic activities. RMR varies according to body size, 
fat mass, age, gender (Tataranni and Ravussin, 1995). It makes for a large portion of 
the energy expanded nearly 60% to 70% of total daily EE (Ravussin et al., 1986). In 
minimal activity people, RMR represents about two-thirds of their total daily EE; in 
higher activity people, RMR may represent only half of their daily EE (Speakman and 
Selman, 2003). The hypothalamus controls RMR mainly through neuroendocrine 
systems, particularly the hypothalamus pituitary thyroid (HPT) axis (Silva, 2003). 
Regarding physical activity, it is the most variable component; it may account for up 
to 40% of the total daily EE (Westerterp and Kester, 2003). The CNS controls the 
skeletal muscle contraction in exercise, intrinsic spontaneous physical activity, or 
shivering after cold exposure (Rui, 2013). As for thermogenesis, it involves brown 
adipose tissue (BAT) activity (Cannon and Nedergaard, 2004; Contreras et al., 2015; 
Whittle et al., 2011). The brain, mainly the hypothalamus and the brainstem, are 
responsible for the control of BAT thermogenesis through sympathetic projections. 
For example, E2, nicotine, GLP-1R and BMP8B signaling in the brain increases 
thermogenesis by enhancing the sympathetic outflow to BAT (Beiroa et al., 2014; 
Lockie et al., 2012; Martinez de Morentin et al., 2014; Martinez de Morentin et al., 
2012; Seoane-Collazo et al., 2014; Whittle et al., 2012). 
3.3.1. BAT thermogenesis 
BAT is valuable for its role in adaptive thermogenesis (Cannon and 
Nedergaard, 2004). BAT cells are entirely distinct from white adipose tissue (WAT) 
not only histologically and functionally but also at the level of origin (Sanchez-
Gurmaches and Guertin, 2014a, c; Shan et al., 2013). Histologically, BAT adipocytes 
are characterized by the presence of small lipid droplets and numerous mitochondria 
that contain cytochromes pigment, responsible for the brownish colour of BAT (Lim 
et al., 2012a). Functionally, WAT can be considered an energy store in the form of 
triglycerides (TG), BAT burns TG to produce heat. Brown fat is located in different 
body parts in rodents and human. In rodents, it is found in interscapular, periaortic, 
axillary, subscapular, and perirenal regions (Cannon and Nedergaard, 2004). In 




cervical, perispinal and mediastinal regions (Cannon and Nedergaard, 2004; Lidell et 
al., 2014) but also was reported as functional in adults (Ouellet et al., 2012; Virtanen 
et al., 2009).  
 
Figure 6. Human BAT distribution: (A) new-born, (B) 13-year-old boy, (C) adult male. 
Modified From (van Marken Lichtenbelt, 2011). 
Recently, a phenomenon called the browning of WAT has been reported. It 
involves the appearance of a particular type adipocytes called beige, brite, or 
recruitable brown adipocytes in anatomically new locations corresponding to WAT 
(Lee et al., 2014; Lidell et al., 2013; Sharp et al., 2012). Although different in origin 
from the classical BAT adipocytes, they are a true functional adipocytes regarding 
their role in thermogenesis (Petrovic et al., 2010; Seale et al., 2008; Shabalina et al., 
2013) but with lesser capacity in vivo (Keipert and Jastroch, 2014; Nedergaard and 
Cannon, 2013; Shabalina et al., 2013). 
 




In rodents, BAT provides an extra-thermogenic mechanism (non- shivering 
thermogenesis) in cold environment that gives them an alternative to shivering 
thermogenesis of muscles (Cannon and Nedergaard, 2004). The sympathetic nervous 
system (SNS) is essential to activate BAT thermogenesis as reflected by a high 
density of nerve endings in the tissue (Cannon and Nedergaard, 2004; Cao et al., 
2001). Norepinephrine activates an adrenergic receptor that generates signals to 
enhance thermogenesis and stimulate intracellular lipolysis (Cannon and Nedergaard, 
2004). The lack of β1- or β3-adrenergic receptors diminishes BAT thermogenesis in 
mice (Penfornis et al., 2000; Zennaro et al., 1998), and β-adrenergic receptor-deficient 
mice cannot tolerate cold (Kharitonenkov et al., 2005). The thermogenesis of BAT is 
associated with the presence of a mitochondrial membrane protein called the 
uncoupling protein-1 (UCP-1), or thermogenin, that is present in the inner 
mitochondrial membrane of BAT adipocytes. This protein enhances thermogenesis 
through uncoupling between respiratory chain complexes and the adenosine 
triphosphate (ATP) production (Cannon and Nedergaard, 2004; Whittle et al., 2011; 
Zingaretti et al., 2009) promoting the free movement of protons into the mitochondrial 
matrix, thus generating heat instead of ATP (Cannon and Nedergaard, 2004; Garlid et 
al., 2000; Jaburek et al., 2001; Whittle et al., 2011).  
Many hypothalamic nuclei are associated with the regulation of thermogenesis, 
reports using retrograde viral tracing by using trans-neuronal pseudorabies virus in rat 
BAT area revealing the potential connection with the preoptic area (POA), PVH, 
DMH, and LHA (Cano et al., 2003; Oldfield et al., 2002). The POA is considered the 
classical center responsible for thermoregulation; it was thought to be the only brain 
center involved in the process due to the presence of temperature-sensitive neurons 
(Boulant, 2000). The POA receives incoming signals from cold- and warm-sensitive 
receptors over the body (Bratincsak and Palkovits, 2004). It has been reported that 
both glutamatergic and electric stimulation of the POA results in enhanced BAT 
thermogenesis (Holt et al., 1987; Nakamura and Morrison, 2008; Thornhill and 
Halvorson, 1994). Regulation of brown fat activity also involves the central 
melanocortin system. The central administration of MC3-R or MC4-R agonists 




Muller et al., 1997; Vaughan et al., 2011), the opposite response resulted from their 
inhibition (Kooijman et al., 2014).  
In regarding the crosstalk between VMH and BAT, it has been known for a 
long time despite the fact that the specific molecular mechanisms have been recently 
reported. Electrical stimulation of the VMH was associated with an increase in 
interscapular BAT temperature that was blocked by β–adrenergic antagonists (Holt et 
al., 1987; Hugie et al., 1992; Kelly and Bielajew, 1991; Perkins et al., 1981). 
Stereotaxic specific administration of glutamate (Amir, 1990; Hugie et al., 1992; 
Yoshimatsu et al., 1993), hydroxybutyrate (Sakaguchi et al., 1988), norepinephrine, 
serotonin, and tryptophan (Sakaguchi and Bray, 1989) into VMH activated BAT. 
More recently, genetic evidence has also supported the role of the VMH in the 
modulation of BAT thermogenesis. For example, VMH- SF-1 knockout reported 
reduced EE and BAT expression of UCP1 (Jo, 2012; Kim et al., 2011).  
Recently, the impact of AMPK in the VMH emerged as a part of the 
mechanisms that regulates BAT activity. There is an inversely correlation between 
VMH AMPK activity and BAT thermogenesis as reported in different studies 
including thyroid hormone, estradiol (E2), BPM8b, and nicotine (Lopez et al., 2010b; 
Martinez de Morentin et al., 2014; Martinez de Morentin et al., 2012; Seoane-Collazo 





Figure 8. Hypothalamic regulation of BAT thermogenesis (Contreras et al., 2015). 
BAT expresses estrogen, progesterone, and testosterone receptors (Rodriguez-
Cuenca et al., 2007). Many studies support the difference in the effect of sex steroids 
on BAT thermogenesis between genders both in human and animals. In humans, 
computed tomography scans showed that active BAT is more abundantly present in 
women than men (Au-Yong et al., 2009; Cypess et al., 2009; Perkins et al., 2013) that 
may result from their greater sensitivity to cold (McArdle et al., 1984). In small 
animals, females appear to have larger BAT (Justo et al., 2005; Rodriguez-Cuenca et 
al., 2002; Rodriguez et al., 2001), larger mitochondria (Rodriguez-Cuenca et al., 
2002), as well as higher GDP-binding indicator of increased UCP1 activity (Quevedo 
et al., 1998) than males. Regarding the metabolic and thermogenic activity of BAT, 
the lipid droplets in BAT adipocytes become more abundant and larger with estradiol 
and progesterone compared to testosterone, suggesting higher cellular metabolic 




pregnancy and lactation to preserve energy (Frontera et al., 2005). VMH silencing of 
the ERα resulted in weight gain, visceral adiposity, increased food intake, and a 
decrease in BAT thermogenesis (Xu et al., 2011b). On the contrary, many in-vitro 
scientific studies reported that testosterone was associated with a reduction in 
thermogenic capacity. It resulted in a decreased in the expression of UCP-1 
(Rodriguez et al., 2002), as well as a reduction in both the abundance of lipid droplets 
(Rodriguez et al., 2002) and lipolytic activity (Monjo et al., 2003). Rodent models 
showed that testosterone was associated with decreased body mass with increased 
RMR (Abelenda et al., 1992; LeBlanc et al., 1998).  
4. Hypothalamic lipid metabolism 
As previously illustrated, the regulation of energy balance regulation is an 
interaction between many factors including the circulating nutrients, different 
hormones and peptides, and neuropeptides. Recently some basic cellular metabolic 
pathways have proven to play a remarkable part in this physiological network. Current 
evidence supports a potential critical role for the hypothalamic malonyl-
CoA/carnitine-palmitoyl transferase 1 (CPT1)/long chain fatty acyl-CoA (LCFAs-
CoA) axis, de novo lipolysis and fatty acid oxidation pathways, in regulating body 
mass and peripheral glucose homeostasis (Yue and Lam, 2012). This pathway can be 
concise into the hypothalamus sensing a physiological rise in fatty acids content in the 
circulation to regulate glucose homeostasis. 
Malonyl-CoA is derived from acetyl-CoA by the catalytic enzyme acetyl-CoA 
carboxylase (ACC) (Dieguez et al., 2009; Lam et al., 2005). Excess glucose elevates 
pyruvate that is converted into acetyl-CoA through a serious of enzymatically 
catalyzed reactions in the cytoplasm and mitochondria (Dieguez et al., 2009). Both 
Acetyl-CoA and malonyl-CoA are substrates for the enzymatic reactions catalyzed by 
fatty acid synthase (FAS) to produce palmitate that is stored depending on the 
metabolic demands of the cell as a de novo synthesized fatty acids (Dieguez et al., 
2009). Neurons use them mainly for the membrane synthesis and rarely as a fuel (Yue 
and Lam, 2012). Fatty acids are also derived from the diet. Circulating long-chain 
fatty acids (LCFAs) gain entrance in the brain by either passive diffusion (Hamilton 




(ACSs) esterifies these LCFAs into LCFA-CoAs. CPT-1 imports the LCFA-CoAs 
into the mitochondria to undergo β-oxidation (Caspi et al., 2007). Malonyl-CoA 
inhibits CPT-1 activity endogenously (McGarry et al., 1977; McGarry et al., 1983). 
Fatty acid oxidation is regulated by the availability of malonyl-CoA, which inhibits 
CPT-1 activity.  
Malonyl-CoA is believed to be the main substrate in this axis as it is involved 
in both de novo lipogenesis and fatty acid oxidation pathways. Any alterations in the 
activities of ACC, MCD and FAS, will subsequently affect the level of malonyl-CoA. 
The level of phosphorylation of AMPK regulates the activities of ACC and MCD. 
Activation of AMPK phosphorylates and inhibits ACC, activates MCD (Dowell et al., 
2005; Lage et al., 2008; Lopez et al., 2007a; Ruderman et al., 2003), and inhibits FAS 
(Lopez et al., 2008; Zhou et al., 2001). With hypothalamic AMPK activation, 
hypothalamic glucose sensing fail to inhibit glucose production while AMPK 
inhibition suppressed glucose production (Yang et al., 2010). The hypothalamic level 
of malonyl-CoA is dynamically altered by fasting/feeding conditions and 
subsequently changes the feeding behaviour (Hu et al., 2003; Wolfgang and Lane, 
2006). Centrally or peripherally treated mice with FAS inhibitors exhibited an 
increase in the hypothalamic malonyl-CoA and hypophagia (Hu et al., 2003; Loftus et 
al., 2000). Conversely, administration of ACC inhibitor decreases hypothalamic 
malonyl-CoA reverses inhibition by FAS inhibitors; resulting in hyperphagia (Hu et 
al., 2003). Furthermore, pharmacological inhibition or genetic ablation of 
hypothalamic CPT1c activity decreased food intake (Obici et al., 2003; Wolfgang et 
al., 2006). While activation of hypothalamic CPT1 alongside the reduction in 







Figure 9. Hypothalamic lipid metabolism and energy homeostasis (Dieguez et al., 
2009). 
 
5. AMP-activated protein kinase (AMPK); the master energy sensor 
AMPK, an enzyme that belongs to kinase family, is expressed in eukaryotic 
cells. It is abundantly expressed in different brain areas including the hypothalamus 
and hindbrain (Kola, 2008; Turnley et al., 1999). Purification and cloning of the 
mammalian AMPK showed that it consists of a heterotrimeric complexes of a single 
catalytic subunit with two isoforms (α1 or α2) and two accessory subunits termed β 
with two isoforms (β1 or β2)  and γ with three isoforms (γ1, γ2, or γ3) (Davis et al., 
2004; Hardie, 2008, 2013; Mitchelhill et al., 1994). The β and γ subunits are 
indispensable for the α-catalytic subunits optimal activity (Chen et al., 1999). AMPK 
is a sensor of the cellular energy status; it become activated by high AMP: ATP or 




consumption as hypoxia and hypoglycemia (Carling et al., 2011; Hardie, 2014; Hardie 
et al., 2012). The activated AMPK strives to restore energy balance by enhancing all 
catabolic processes producing ATP such as fatty acid oxidation while hindering ATP 
consuming activities such as fatty acid synthesis (Hardie, 2007; Hardie et al., 2012). 
 
Figure 10. Structure and regulation of AMPK. Modified from (Lopez et al., 2016). 
Recent reports showed the pivotal role of AMPK in the control of the whole 
body energy balance through its central action in the hypothalamus, aside from its role 
at the cellular level. AMPK is expressed in some hypothalamic nuclei involved in the 
central regulation of energy balance including the ARC, VMH, PVH and LHA 
(Minokoshi et al., 2004). Its level fluctuated with energy status, fasting enhances 
AMPK activity, while refeeding inhibits it in many hypothalamic regions (Andersson 
et al., 2004; Minokoshi et al., 2004).  Also, hypothalamic AMPK activation results in 
hyperphagia and weight gain, while its inhibition reduces feeding and weight loss 
(Andersson et al., 2004; Lopez et al., 2008; Minokoshi et al., 2004).  
Hormonal regulation of hypothalamic AMPK activity also has been reported. It 
is activated by orexigenic signals such as ghrelin, glucocorticoids, adiponectin (Gao et 
al., 2013; Guillod-Maximin et al., 2009; Kubota et al., 2007; Lopez et al., 2008; 
Shimizu et al., 2008). It is also inhibited by anorexigenic signals such as leptin, 




Minokoshi et al., 2004; Namkoong et al., 2005; Seo et al., 2008). Genetic animal 
models have also enforced the role of hypothalamic AMPK in energy homeostasis. 
Global AMPKα2 knockout resulted in weight gain and adiposity under HFD condition 
(Viollet et al., 2003). Also, neuron-specific knockout of AMPK α2 such as POMC 
neurons (POMCα2KO) resulted in an increase in body weight and adiposity under 
standard and HFD feeding conditions (Claret et al., 2007). Conversely, mice with 
AMPKα2 deficient AgRP neurons had age-dependent leanness (Claret et al., 2007).  
 
Figure 11. AMPK regulation of metabolism. Modified from (Novikova et al., 2015). 
 
6. Sex steroids and energy homeostasis 
Sex hormones, particularly estradiol, have a clear impact on the regulation of 
energy balance. For example, estrogen deficiency resulted in higher energy intake and 
increased body weight in ovariectomized rodents and post-menopausal women. Of 
note, this effect can be reversed by treatment with steroid hormones.  Sex steroid 
hormones (estrogens, progestins, and androgens) are not only participating in normal 




secreted by the gonads or to a lesser extent synthesized locally in extragonadal tissues 
(estradiol and progesterone by the ovary and testosterone by the testis). The 
hypothalamic-pituitary-gonadal axis (HPG axis) points to the relation between the 
hypothalamus, pituitary gland, and gonads. Sex steroid hormones are secreted in 
response to gonadotropins released from the anterior pituitary induced by 
gonadotropin-releasing hormone (GnRH) from the hypothalamus. It is evident that 
gender, reproduction, and energy metabolism are interrelated (Hill et al., 2008). 
Any severe changes in the energy balance such as obesity, anorexia, and 
cachexia have a negative influence on fertility (Cardozo et al., 2012; Du Plessis et al., 
2010; Sermondade et al., 2012). Sex steroid hormones play important roles in 
regulating energy metabolism as evidenced by the fact that lacking estrogen or 
androgen predispose to obesity and its associated comorbidities including diabetes and 
cardiovascular diseases (Carr, 2003; Zitzmann, 2009). Also, in humans, gender is 
associated with differences in energy metabolism due to the action of sex steroid 
hormones while sex-specific specialization is linked to distinct body fat distribution 
and energy substrate utilization patterns (Varlamov et al., 2014). 
 
6.1. Estrogens 
Estrogens, a potent steroid hormone present in high levels in females from 
adolescence to menopause and low levels in men, are complex hormones with 
pleiotropic effects. There are three main forms of estrogens in mammals, estrone (E1), 
17β-estradiol (E2), and estriol (E3) (Kamat et al., 2002). E2 being the most active 
metabolite. Estrogens secreted from the ovaries of women with normal menstrual 
cycles or extra-ovarian synthesized at local tissues in postmenopausal women and 
men as a paracrine or autocrine factor (Simpson et al., 2005). The ovary of 
premenopausal women primarily produces E2 in the growing follicles. Estrogens are 
also synthesized by the placenta, the adrenals, and testes (Kamat et al., 2002). The 
placenta is widely responsible for the high levels of estrogens, mainly E3, during 
pregnancy. The role of adipose tissue derived estrogens remains not very clear (Kim et 
al., 2014). The ovary of premenopausal women primarily produces E2 in the growing 




model (Hillier et al., 1994; Lopez and Tena-Sempere, 2015). In the growing follicle, 
both theca and granulosa cells are necessary for the synthesis of ovarian estrogens. In 
the inner theca cell layer, the luteinizing hormone stimulates the conversion of 
cholesterol into androgens such as androstenedione and testosterone. The newly 
synthesized androgens move to granulosa cells layer to be converted into estrogens in 
a reaction catalysed by aromatase enzyme under the influence of the follicle-
stimulating hormone (FSH) (androstenedione to E1 and testosterone into E2). E1 can 
be further converted into E2 by the enzyme, 17-β hydroxysteroid dehydrogenase (17-β 
HSD) while both E1 and E2 can be precursors for the synthesis of E3 (Kamat et al., 
2002). Tissue estrogen sulfotransferase (EST) is a critical mediator of estrogen action; 
it is responsible for suppressing estrogen activity by conjugating sulfonate group to 
prevent its binding to ERs and enhance the urinary excretion of the hormone (Strott, 
1996). 
 
Figure 12: Ovarian estrogen synthesis by the two-cell, two-gonadotropin model. Modified 





Estrogens not only control female fertility and numerous reproductive functions 
(Garcia-Galiano et al., 2012) but also are involved in cognition, neuroprotection and 
cellular metabolism (Arevalo et al., 2015; Garcia-Galiano et al., 2012). E2 is involved 
in controlling many cellular functions at the different body tissues; a- at the central 
level in hypothalamic nuclei control food intake, energy expenditure, and WAT 
distribution, and b- at the periphery in insulin secretion and sensitivity as well as 
prevention of lipid accumulation (Garcia-Galiano et al., 2012).  
6.1.1. Estrogens: modes of action and regulatory mechanisms  
Estrogens mediate their biological effects through binding to estrogen receptor 
(ER). There are two classical estrogen receptors (ER): ERα and ERβ that has multiple 
isoforms, different tissue expression patterns, and functions (Nilsson et al., 2001). In 
humans, ERα has three isoforms (ERα1- 3), while ERβ has five isoforms (ERβ1-5) 
(Leung et al., 2006; Matthews and Gustafsson, 2003; Ogawa et al., 1998). The 
variation in ER distribution may be governing factor responsible for tissue-specific 
response to estrogen (Knowlton and Lee, 2012). ERα and β are found in the cytoplasm 
and the nucleus in caveolae-associated with the plasma membrane (Acconcia et al., 
2005; Chambliss et al., 2000). ERα forms complexes with caveolin 1, c-Src, Akt, 
PI3K, HSP90 and eNOS in caveolae in the plasma membrane (Haynes et al., 2003; 
Kim and Bender, 2009; Li et al., 2003). Estrogens, lipophilic in nature, are readily 
diffused through cellular membranes and interact with intracellular ERs (Nadal et al., 
2001; Paterni et al., 2014). Upon activation of ERs, classical and non-classical 
pathways for mediating the estrogenic effects have been suggested.  
The classical pathway of action of ERs involves them operating as ligand-
activated transcription factors that, upon ligand binding, form dimers to bind directly 
to an estrogen response element (ERE) in target gene promoters to produce gene 
expression (Nadal et al., 2001; Paterni et al., 2014; Safe and Kim, 2008) in a genomic 
mechanism that involves ERE-dependent effects. The other non-classical mechanisms 
do not imply ERE action. It might be through indirectly binding to DNA through 
protein-protein interactions with other DNA-binding transcription factors in the 
nucleus or membrane-associated ERs mediate nongenomic effects (Bjornstrom and 




negatively feedback on gonadotropin secretion (Glidewell-Kenney et al., 2007), as 
well as energy metabolism related actions (Liu and Mauvais-Jarvis, 2010). ERα 
activation partially mediates its effect in energy homeostasis through then on ERE 
pathways, as the genetic rescue of nonclassical ERα signalling in a global ERα-
knockout (KO) mouse was enough to restore nearly the main metabolic parameters to 
normal values (Park et al., 2011). 
In the non-genomic pathway, activation of membrane-associated ERs activates 
a signalling cascade that includes PI3K and Akt, ERK 1/2, JNK and p38 (Patten et al., 
2004; Wang et al., 2006; Wang et al., 2009; Wu et al., 2011). This signalling cascade 
is responsible for protecting against cell injury, except for JNK, that 
increases apoptosis. More recently, G-protein-coupled estrogen receptor (GPER) has 
been reported as a membrane-associated ER (Deschamps and Murphy, 2009). It is 
responsible for mediating a rapid cellular response to estrogens (Noel et al., 2009; 
Thomas et al., 2005). This receptor is also known as G-protein coupled receptor 
30 (GPR30), or more recently GPER1 and the membrane estrogen receptor (mER). 
GPER1 has been shown to contribute to E2 mediated vasodilation (Lindsey et al., 
2011). The genetic ablation of GPER1 has been associated with some of estrogen 
insufficiency outcomes such as increased body weight and glucose intolerance but not 






Figure 13: Mechanism of action of ERα. (a) Classic genomic signalling. (b) ERE-
independent genomic signalling, (c, d) Non-genomic mode of action (c) positive or (d) 
negative regulation of transcription. Modified From (Manolagas et al., 2013).  
It is also worth mentioning that the estrogen-related receptors (ERRs), a family 
of orphan nuclear receptors, with three isoforms (alpha, beta and gamma) are involved 
in energy metabolism and mitochondrial biogenesis (Dufour et al., 2007; Giguere, 
2008). Their activity depends on the peroxisome proliferator-activated receptor 
coactivator-1 family proteins (Giguere, 2008; Schreiber et al., 2003). Activated ERα 
has been reported to upregulate ERRα expression with many similarities in the ER and 
ERR response elements (Giguere, 2002). To date, no ligand for these receptors is 
known as well as any known estrogen action. 
It has been suggested that the estrogenic effect on energy balance are mostly 
mediated by ERα (Mauvais-Jarvis et al., 2013). ERKOα mice models were 




al., 2001; Heine et al., 2000; Ohlsson et al., 2000). Aromatase enzyme KO (ArKO) 
mice models were associated with obesity (Jones et al., 2000). Patients suffering from 
the lack of aromatase enzyme also suffered from obesity (Grumbach and Auchus, 
1999). On the other hand, knocking out of ERβ was not associated with any energy 
imbalance changes (Ohlsson et al., 2000). In keeping with this evidence, it was also 
shown that propylpyrazoletriol (PPT), selective ERα agonist, was associated with a 
loss of appetite, meanwhile, diaryl propionitrile (DPN), selective ERβ agonist, was not 
(Martinez de Morentin et al., 2014; Martinez de Morentin et al., 2015; Roesch, 2006). 
6.1.2. Estrogens and the control of energy homeostasis 
In the recent years, estradiol has proven to play a vital role in the control of 
energy homeostasis both at central level acting directly on the hypothalamus and at 
the periphery through hormonal regulation such as adipokines and insulin (Clegg et 
al., 2006). The incidence of obesity is higher in postmenopausal than premenopausal 
woman owing to the low estrogen level (Garcia-Galiano et al., 2012). Also 
ovariectomized rats were hyperphagic with higher body weight (Martinez de Morentin 
et al., 2014; Martinez de Morentin et al., 2015; Mauvais-Jarvis et al., 2013). Estrogen 
replacement therapy has proven to be of value in both postmenopausal women and 
ovariectomized rats (Martinez de Morentin et al., 2014; Martinez de Morentin et al., 
2015; Mauvais-Jarvis et al., 2013). Recently it was reported that estrus cycle 
(Martinez de Morentin et al., 2014), as well as gestation and lactation (Martinez de 
Morentin et al., 2015),  are associated with changes in energy homeostasis. 
6.1.2.1.  Peripheral actions of estrogens in the control of energy homeostasis 
Recent reports have mentioned a cross-talk between estrogen and leptin, a 
peptide hormone secreted by adipocytes. Leptin has a direct effect on ERα, it activates 
and increases its expression (Catalano et al., 2004; Fusco et al., 2010). As mentioned 
earlier estrogen can be synthesized locally in the adipose tissue in a reaction catalysed 
by the aromatase enzyme, Leptin has been shown to increase aromatase expression 
(Catalano et al., 2003). Further, leptin receptor (Ob-R) and ERα shows several 
interactions where Ob-R STAT-3 activation is enhanced by ERα expression (Binai et 
al., 2010). Estrogen can directly stimulate leptin expression as shown in mice models; 




in mammary tumors (Morad et al., 2014). Estrogens were suggested to regulate 
positively leptin gene expression (Alonso et al., 2007). Studies on rat isolated 
adipocytes showed the influence of estradiol on leptin gene expression (Brann et al., 
1999). The central actions of leptin were found to be attenuated in association with 
low estrogen levels (Alonso et al., 2007; Mistry et al., 1999). 
Cholecystokinin (CCK), a gut peptide and a satiety signal (Beglinger and 
Degen, 2004), is also affected by estrogen. Estrogens increase CCK satiating effect as 
evidenced by intraperitoneal administration of CCK produced satiation during 
proestrus or estrus, but not during diestrus. The effect of CCK-1R antagonist was 
more prominent during estrus than during diestrus and only evident after puberty, 
estradiol replacement therapy in ovariectomized rats augmented the effect of 
intraperitoneal administration of CCK (Asarian and Geary, 1999, 2007, 2013; Butera, 
2010; Butera et al., 1993; Eckel, 2004). Estrogens mainly activate ERα to increase 
CCK satiating effect wherein ovariectomized ERα KO mice, the effect of CCK-1R 
antagonist was not potentiated by estradiol injection (Geary et al., 2001). Glucagon-
like peptide-1 (GLP-1) is a gut peptide and a satiety signal (Barrera et al., 2011; 
Turton et al., 1996). It has been reported that in ovariectomized rats, estradiol 
potentiates both the satiating effect of GLP-1 (Asarian and Geary, 2013) and the de-
satiating effect of the GLP-1 receptor antagonist exendin-9 upon intraperitoneal 
administration of either (Asarian et al., 2012; Asarian and Geary, 2013). Glucagon, a 
peptide hormone, secreted by the intestine and pancreas during meals to produce anti-
insulin-like effect (Habegger et al., 2010). Estradiol increased both the satiating effect 
of intra-meal hepatic portal infusions of glucagon as well as the de-satiating glucagon 
antagonist by hepatic portal infusion of glucagon antibodies in ovariectomized rats 
(Geary and Asarian, 2001).  
Ghrelin is a gut peptide synthesized and secreted from the stomach to stimulate 
appetite (Kojima et al., 1999). Intraperitoneal and central ghrelin injection in 
ovariectomized rats was associated with higher appetite stimulation than intact rats or 
estradiol-treated ovariectomized rats with cycle variation, during diestrus than 
proestrus or estrus (Clegg et al., 2007). Ghrelin mRNA levels showed cyclic variation 




fact that estrogens affect meal size not frequency, it has been reported that the effect 
of ghrelin was associated with changes in meal frequency, but not size, in 
ovariectomized rats (Butera, 2010; Clegg et al., 2007). Ghrelin and its receptor were 
reported to be expressed in ovary, and placenta of rat (Budak et al., 2006; Caminos et 
al., 2003; Gaytan et al., 2005; Gualillo et al., 2001; Otto et al., 2001) and ERα is 
expressed in gastric mucosa (Clegg et al., 2007). Temporary elevation in both the 
number of ghrelin-expressing cells in the gastric mucosa as well as plasma ghrelin 
level upon ovariectomy was reported (Clegg et al., 2007; Matsubara et al., 2004; 
Sakata et al., 2006).  
The interaction between estrogens and insulin can be interpreted from the 
development of both obesity and insulin resistance in both ERα knockout (Heine et 
al., 2000) and aromatase knockout mice (Takeda et al., 2003). The low estrogen levels 
rendered both ovariectomized rats (Alonso-Magdalena et al., 2008) and 
postmenopausal women (Livingstone and Collison, 2002) makes them more 
susceptible to impaired glucose tolerance and insulin resistance. Estrogen supply to 
both cases was enough to protect (Godsland, 1996). Central administration of insulin 
inhibited feeding in males more than females (Clegg et al., 2006; Clegg et al., 2003). 
Central or peripheral administration of estradiol decreased the feed inhibition effect of 
centrally administered insulin in ovariectomized rats (Clegg et al., 2006). 
Current reports on the estrogenic effect of adipose tissue have shown that they 
interfere with fat distribution pattern (Lovejoy et al., 2009), and differentiation (Lapid 
et al., 2014) as well as lipid metabolism (Varlamov et al., 2014). Males has lower 
body fat (mostly intra-abdominal) than females (mostly gluteal and subcutaneous) 
(Bjorntorp, 1992; Bouchard et al., 1993). Post-menopausal women suffer from a 
change in fat distribution, tends to accumulate intra-abdominal fat (Guthrie et al., 
2004; Lovejoy et al., 2008) that was prevented by estrogen supplying (Gambacciani et 
al., 1997). In ovariectomized rats, both central and peripheral administration of 
estradiol restores fat distribution to normal as well as their central leptin sensitivity 
(Clegg et al., 2006). Estrogens are locally synthesized in the adipocytes and their level 
correlate to the total adiposity (Tchernof et al., 1995). ERα presents in the adipose 




visceral fat compartment and to a lesser extent in the inguinal fat (Heine et al., 2000). 
On the other hand, ERβKO mouse was not associated with obesity (Ogawa et al., 
1999).  
In ovariectomized mice, estradiol injection reduced adipocyte size by 
decreasing fatty acid uptake and lipogenesis (D'Eon et al., 2005). Estrogens also 
enhance browning of the adipose tissue; females have a higher metabolic rate of fat 
than males as well as expression levels of uncoupling protein one (UCP-1) (Cypess et 
al., 2009; Nookaew et al., 2013). Estrogens may enhance browning through regulating 
both the natriuretic proteins ANP (atrial natriuretic peptide) and BNP (brain 
natriuretic peptide) (Bordicchia et al., 2012; Collins, 2014). The levels of ANP and 
BNP were greater in premenopausal women than men and were reduced in 
premenopausal women (Jankowski et al., 2001; Wang et al., 2002). 
 
6.1.2.2. Central effects of estrogens in the control of energy homeostasis  
Estrogens provide protection against the development of obesity and its 
associated comorbidities (Dye and Blundell, 1997). ERs are found all over the CNS 
(Merchenthaler et al., 2004; Pitteloud et al., 2005) as well as in the different 
hypothalamic nuclei in rodent brain including the ARC, VMH, PVH, and POA 
(Osterlund et al., 1998; Shima et al., 2003; Simerly et al., 1990). Several reports have 
concluded that estrogens are involved in the hypothalamic modulation of energy 
balance through action particularly in the ARC and the VMH where ERα is more 
abundantly expressed than ERβ. Estradiol-mediated actions related to energy 
homeostasis are mainly associated with ERα (Heine et al., 2000). Central 
administration of estradiol has a food inhibitory effect (Martinez de Morentin et al., 
2014). Likewise, ERα deficiency in female mice was associated with obesity and 
weight gain through increasing energy intake and decreasing expenditure (Heine et al., 
2000; Ribas et al., 2010). ERβ is also involved as ICV administration of ERβ 
antisense oligodeoxynucleotides blocks the estrogenic effect of centrally administered 
estradiol in female rats (Liang et al., 2002). Also, in HFD-fed female mice, ICV 
injection of ERβ-selective agonist was associated with elevated BAT UCP-1 




In the ARC, ERα is prominently expressed in POMC neurons, the levels of 
POMC expression is dramatically increased with the higher estradiol level in proestrus 
(Bohler et al., 1991; Wise et al., 1990). On the other hand, ERα KO mice have a 
decreased POMC expression levels (Hirosawa et al., 2008), a situation that is also 
found in ovariectomized rats, where this action was reversed with estradiol treatment 
(Martinez de Morentin et al., 2014; Pelletier et al., 2007). Also, other evidence from 
mice showed an increase in the excitatory synapses on POMC neurons in proestrus or 
after estradiol treatment (Gao et al., 2007). Estrogens act directly on POMC neurons 
and regulate their cellular activity. MC4receptor antagonists Shu 9119 or agouti-
related peptide (AgRP) blocked the estradiol action on food intake in rats (Polidori 
and Geary, 2002). In mice, deletion of ERα from POMC neurons has resulted in an 
increase in food intake (Xu et al., 2011b). 
The reported evidence about the effect of estradiol on AgRP/NPY neurons in 
the ARC is inconsistent. A report using in vitro studies suggested that there is an 
inverse correlation between ERα abundance and NPY expression, as well as a direct 
correlation between ERβ abundance and NPY expression (Titolo et al., 2006). On the 
contrary, ovariectomized rats showed an increased level of NPY expression that was 
reversed by estrogen treatment (Martinez de Morentin et al., 2014; Pelletier et al., 
2007). About the estrus cycle, the NPY expression levels were the lowest during 
estrus (Olofsson et al., 2009). This report also shows that E2 administration decreased 
the fasting-induced c-Fos activation in NPY/ AgRP neurons and stopped the refeeding 
response (Olofsson et al., 2009). Co-localization of the RB isoform of the leptin 
receptor (Leprb) with ERα in the ARC was reported (Diano et al., 1998). Leprb 
mRNA expression is down-regulated by estrogens in the ARC (Bennett et al., 1999), 
possibly via an ERE on the leptin receptor gene (Lindell et al., 2001) suggesting a 
crosstalk between their effects in the regulation of energy balance. Expression of the 
leprb isoform was higher during estrus and metestrus, although no changes in the 
circulating leptin levels (Bennett et al., 1999).  
Recent evidence has reported that ERα activation in VMH neurons plays a 
major role in regulating physical activity, thermogenesis, and fat distribution. The 




(Ikeda et al., 1995), its deletion disrupts the VMH structure (Dellovade et al., 
2000)and leads to obesity (Majdic et al., 2002). Electrophysiological studies of the 
VMH neurons showed direct estrogen effects on these neurons (Minami et al., 1990). 
More recent studies on ERα gene silencing and transgenic mice showed reduced 
sensitivity to E2-induced weight loss, increased visceral fat deposition, and reductions 
in energy expenditure without any changes in food intake (Musatov et al., 2007; Xu et 
al., 2011b). 
6.2. Androgens 
Androgens have been implicated as having an important role in many vital 
processes other than regulating the reproductive function including energy 
homeostasis (Navarro et al., 2015; Shen and Shi, 2015; Wilson, 1999). Testosterone 
(T) and 5α-dihydrotestosterone (DHT) are considered the main androgens, T is 
synthesized primarily by the Leydig cells in the testes and can be converted into DHT 
in a reaction catalysed by 5-α-reductase enzyme (Martini et al., 1993; Puri and 
Walker, 2016). DHT is considered the most active form of endogenous androgens, 
although less abundant; it is more biologically active than T (Matsumoto et al., 2013; 
Mitchell, 2012). Androgens mediate their different actions via binding to the androgen 
receptor (AR), a single nuclear receptor (Mangelsdorf et al., 1995). The AR is a 
member of the steroid hormone group including the ER, glucocorticoid receptor (GR), 
progesterone receptor (PR) and mineralocorticoid receptor (MR) (Mangelsdorf et al., 
1995; Nuclear Receptors Nomenclature, 1999). Other types of androgens can be 
synthesized locally in the Zona reticulata and zona fasciculata of the adrenal cortex 
including dehydroepiandrosterone (DHEA) and androstenedione (Lasley et al., 2011).  
The synthesis of testosterone in Leydig cell is controlled by stimulation of the 
release of the LH from the pituitary gland in response to GnRH release from the 
hypothalamus (Stocco, 2001). LH initiates the process of steroidogenesis by 
promoting the steroidogenic acute regulatory protein (StAR) expression that enhances 
the inner mitochondrial uptake of cholesterol (Shima et al., 2013; Stocco, 2001). This 
cholesterol is used to produce pregnenolone that is converted to DHEA, that produces 
androstenediol and androstenedione that produces testosterone via reaction catalyzed 




dehydrogenase, 17-α-hydroxylase/17, 20-lyase P450 (CYP17A1), and 17-β 
hydroxysteroid dehydrogenase type III (HSD17-β3) (Habert et al., 2001; Miller and 
Auchus, 2011; O'Shaughnessy et al., 2006; Scott et al., 2009). Androgens are also 
expressed in females; it is synthesized mainly in the ovaries and the adrenal cortex 
(Burger, 2002). Once produced, circulating testosterone is mostly bounded to serum 
sex hormone-binding globulin (SHBG) and albumin (Thaler et al., 2015). 
 
Figure 14. The hypothalamic–pituitary–testicular axis control of androgen synthesis. 





6.2.1. Androgens: modes of action and regulatory mechanisms  
The structure of the AR is similar to the other nuclear receptors. It consists 
mainly of4 functional domains: a- an amino-terminal transactivation domain; b- a 
highly conserved central DNA-binding domain (DBD); c- a hinge region and d- a 
carboxy-terminal ligand-binding domain (LBD), to which the androgen binds (Chawla 
et al., 2001). Androgens are lipophilic hormones; they can readily diffuse across the 
lipid bilayer membrane of the cell without the aid of a transport protein (Quigley et 
al., 1995).AR present normally in the cytoplasm in complexes with heat-shock 
proteins (HSPs). Upon activation AR is displaced from HSPs, the N and C terminals 
of the AR interact and binds importin-α to translocate the AR into the nucleus 
(Prescott and Coetzee, 2006; Srinivas-Shankar and Wu, 2006). Ligand-activated AR 
forms a homodimer that binds to androgen response elements (AREs), specific DNA 
sequences, in regulatory regions of target genes (Mangelsdorf et al., 1995). Once 
bound to its response element, AR initiates gene transcription by the recruitment of 
chromatin modifying and remodelling complexes, co-regulators and other 
transcriptional factors (Belandia and Parker, 2003; Dilworth and Chambon, 2001; 
Lemon and Tjian, 2000; Orphanides and Reinberg, 2002). This mechanism is 
considered to be the genomic pathway of androgen signaling (Heemers and Tindall, 
2007).  
Recent reports from in vitro studies have supported the presence of a non-
genomic pathway that is responsible for rapid, non-ARE dependant androgenic effects 
mediated by a plasma membrane–associated AR (Bennett et al., 2009; Lamont and 
Tindall, 2011). This pathway is suggested to be responsible for the rapid intracellular 
actions such as stimulating different intracellular signaling pathways through direct 
contact with signal transducers and/or activation of kinases (Ma et al., 2001; 





Figure 15. Mechanism of action of AR. Modified from (Mills, 2014). 
Many factors are involved in influencing the overall activity of AR function other 
than ligand binding. Of which, tissue distribution and levels of AR expression appears 
to be prominent. AR is expressed in the adrenal gland, the epididymis, prostate, 
skeletal muscle, kidney, liver, and heart. Androgen is known to upregulate the AR 
expression as well as FSH, prolactin, and epidermal growth factor (Keller et al., 
1996). Also, the post-translational modifications of the AR, including acetylation, 
phosphorylation, ubiquitination, and sumoylation influence the activity of the AR 
(Burgdorf et al., 2004; Poukka et al., 2000; Wen et al., 2000). Phosphorylation of the 
AR increases AR activity independently of ligands while sumoylation decreases the 
activity in the presence of ligands. Phosphorylation may enhance the affinity of the 
AR for coregulators, resulting in increased transactivation. Co-regulators interact with 
either activated or ligand-free receptors and modulate receptor activity by remodelling 
chromatin by their intrinsic histone acetylation (HAT), or deacetylation (HDAC) 
activity, or recruit proteins bearing such activities, for the regulation of target genes 




facilitating receptor nuclear trafficking, promoting receptor DNA binding, recruiting 
or function as basal transcription factors (TF), or modifying receptors (Lee et al., 
2001; Ozanne et al., 2000; Yeh et al., 1999). 
6.2.2. Effects of androgens on the regulation of energy homeostasis 
6.2.2.1. Peripheral effects of androgens in the control of energy homeostasis 
In males, the impact of testosterone deficiency on the development of visceral 
obesity, insulin resistance and metabolic syndrome is well established (Khaw and 
Barrett-Connor, 1992; Mauvais-Jarvis, 2011; Zitzmann, 2009; Zitzmann et al., 2006). 
A cross-talk between glucose homeostasis and androgens has been suggested 
depending on the findings that low serum testosterone level predisposes the 
development of diabetes, and hypogonadism is a result of diabetes (Corona et al., 
2011a; Corona et al., 2011b). Also, the amount visceral adiposity inversely correlates 
with the level of serum testosterone in the metabolic syndrome (Khaw and Barrett-
Connor, 1992) as observed in hypogonadism in elder men (Zitzmann et al., 2006), 
inherited testosterone deficiency (Bojesen et al., 2006), and patients with prostate 
cancer treated with androgen deprivation (Basaria et al., 2006). On the other hand, 
high testosterone levels were related to insulin sensitivity (Pitteloud et al., 2005). 
Many scientific reports had demonstrated the anti-obesity effect of testosterone. 
Increased amounts of visceral fat were observed in men with genetic mutations 
causing lower AR-mediated gene transcription (Zitzmann et al., 2003), AR-deficient 
male mice developed late onset visceral obesity with increased lipogenesis in WAT 
and liver (Fan et al., 2005b; Lin et al., 2005).  
Ghrelin levels were found to be positively associated with testosterone levels in 
testosterone-treated hypogonadal men (Pagotto et al., 2003). Also, the relationship 
between adiponectin and testosterone level was suggested, in hypogonadal men, high 
adiponectin levels were found that decreased with testosterone administration 
(Lanfranco et al., 2004). In mice, adiponectin level decreased with testosterone 
administration (Nishizawa et al., 2002). Also, AR-deficient mice showed high 
adiponectin level (Fan et al., 2005b). Testosterone also promotes insulin sensitivity 
through skeletal muscle as it is involved in the regulation of the expression of certain 




marked insulin resistance in skeletal muscle that was abolished by testosterone 
therapy (Holmang and Bjorntorp, 1992). This may be explained by a reduction in the 
transcription factor PGC1α (peroxisome proliferator activated receptor gamma co-
activator alpha), a molecular marker of muscle insulin sensitivity, as its transcription 
was decreased in skeletal muscle of T2D patients (Mootha et al., 2003). Similarly, in 
men with low testosterone or mice deficient in AR low expression levels were found 
in muscle (Fan et al., 2005b; Pitteloud et al., 2005). Recent mice models with a 
specific knock down in hepatocytes AR (HARKO) were valuable to studying the 
effects on the liver. Male mice suffered from hepatic stenosis with high-fat dieting 
(Lin et al., 2008). Also, a β-cell specific AR knockout mice showed a reduced 
glucose-stimulated insulin secretion (GSIS) leading to glucose intolerance and 
develop β-cell failure to compensate for diet-induced insulin resistance (Navarro et al., 
2015).  
6.2.2.2. Central effects of androgens in the control of energy homeostasis 
AR is abundantly expressed in the brain (Fan et al., 2008) with the highest levels 
of expression in the hypothalamus (Simerly et al., 1990). Recent studies on AR-
deficient mice reported the development of obesity in the case of whole body AR-
deficient mice without any elevation in energy intake and a reduced BAT 
thermogenesis which decreases energy expenditure (Fan et al., 2005a). Further studies 
in the same mice model showed the leptins fails to promote STAT3 nuclear 
localization in ARC neurons or to decrease food intake and body weight even before 
the onset of overt obesity (Fan et al., 2008). Other studies on neuronal specific ARKO 
(NARKO) mice reported the development of obesity, insulin resistance, and glucose 
intolerance; they showed hypothalamic insulin resistance through activating 
hypothalamic NFKB that increases inflammation (Yu et al., 2013). All of these 



































































The existence of sexual dimorphism in energy homeostasis and fat distribution is 
well established. Data gleaned in recent years have uncovered the central effects of 
estrogens at the hypothalamus in energy balance through the energy sensor AMPK. 
The main objective of this work was to further evaluate the central effect of sex 
steroids (estrogens and androgens) on energy balance with particular focus on the 
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1. Animal models and housing conditions 
Various animal models were used in the different experiments of this thesis 
including a- Adult male Sprague–Dawley rats (rattus norvegicus) weighting around 
200 – 250 g approximately (8-11 weeks old) from the Animalario General of the 
University of Santiago de Compostela were used in the experiments conducted in the 
androgen experiments.  b- Adult female Sprague–Dawley rats (rattus norvegicus) 
weighting around 250 g approximately (9-11 weeks old) from the Animalario General 
of the University of Santiago de Compostela were used in the experiments conducted 
in the estrogen experiments.    
Upon arrival, All the animals were housed in open cages under conditions of 
controlled illumination of 12-hour light/dark schedule (light: 8:00–20:00 h), humidity, 
and temperature. All animals were allowed ad-libitium access to standard rat chow 
and tap water unless otherwise was specified by experiments. All animals were 
randomly assigned to the different groups of each experiment. We housed five 
animals per cage except for the experiments that require monitoring daily food intake, 
body weight and rectal temperature where they were individually caged. Animal 
welfare was verified periodically through monitoring body weight, food intake, and 
the general well-being of the rats throughout the different experiments. All animals 
were left for approximately one week for accommodation before the start of any 
experiment to avoid generating severe stress during handling by the staff or due to 
changes in the environment. 
All experimental procedures and protocols for handling animals that were 
conducted during the course of this thesis have been previously approved by the head 
of the servicio provincial de ganadería del departamento territorial de la Consellería 
do Medio Rural e do Mar de la provincia de La Coruña (competent to issue the 
decision based on the Decreto 245/2009 of the 3rd of April by which they regulate the 
territorial delegations of the Xunta de Galicia and the Decreto 46/2012 of 19th of 
January that establishes the organizational structure of the Consellería do Medio Rural 
e do Mar e do Fondo Galego de Garantía Agraria). The responsible person of the 
approved protocols was Miguel A. Lopez Perez and conducted under the number of 
procedure identification of: a- 15005AE/10/FUN/FISIO2/MLP2 (under compliance of 
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RD 1201/2005 of October 10, on the protection of animals used for experimentation 
and other scientific purposes), and b- 15010/14/006 (under compliance of the actual y 
vigente RD 53/2013 of 1st of February, that establishes the basic standards for the 
protection of animals used for experimentation and other scientists purposes, 
including teaching), according to current legislation: Ley 30/1992 of 26th of 
November legal regime of public administrations and common administrative 
procedure, modified by Law 4/1999, of January 14, that establishes the decision to 
propose terminating the proceedings that decides all issues raised by whom interested 
and those derived from Decree 296/2008 of 30th December on the protection of 
animals used for experimental and other scientific purposes, including teaching, and 
by which creating the ‘Rexisro de centros de cría’, of suppliers and users and the 
‘Comisión Galega de Benestar de los Animales de Experimentación’ ; Order of 15 
September 2006 establishing the creation of ‘Comité de Bioética da Consellería Rural’ 
; Decrto 153/1998 of 2 April so that approves the regulation implementing Law 
1/1993 of April 13 (protection of domestic and wild animals in captivity); Law 
32/2007 of 7 November, for the care of the animals on the farm, transport and 
slaughter; also following the European Directive on Animal Experimentation 
(2010/63 / EU). 
2. Anaesthesia and analgesia 
To carry out the various surgical procedures in this thesis, animals were treated 
with an intraperitoneal injection (IP) of anaesthetic agent. The composition of 
anaesthetic agent in case of rats was 42.5% ketamine (Imalgene 1000 injection, 
Merial, Barcelona, Spain), 20% xylazine (Rompun 2%, Bayer HealthCare, Berlin, 
Germany) and 37.5 % normal saline (isotonic physiological saline, Physan, Madrid, 
Spain), and the dose used was 200 µl / 100 grams of body mass. 
All anaesthetic and analgesic agents were preserved according to the specific 
recommendations of the suppliers. Both foot and blinking reflexes were used to check 
that each animal is well anesthetized; its absence informs that the surgical procedure 
can be carried out safely and with no pain felt by the animals. After surgical 
procedures, the animals were subcutaneously (SC) treated with ketoprofen as an 
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analgesic (ketoprofen-Orudis 100 mg., Sanofi aventis, Barcelona, Spain) at the dose of 
2.5 mg per kg of body mass. 
3. Routes of drug administration 
Different routes of drug administration were used: 
3.1. Intraperitoneal route (IP) 
This route does not require the use of anaesthesia. It is performed on the 
caudoventral part of the rat beneath the peritoneum. It involves catching the animal 
from the back by using a piece of cloth to immobilize the animal by trying to press the 
forelimbs. The animal's head is tilted slightly downward to minimize the risk of 
tearing the viscera and the needle (BD Microlance, 25G 5/8” 0,5x16mm, BD Medical 
Surgicals Systems) attached to a syringe (1 ml BD slip-tip syringe, bulk, non-sterile, 
BD Medical Surgical Systems) is inserted in a perpendicular manner to this, preferably 
in the right side. This route was used for administration of the anaesthetic agents as 
previously mentioned. 
3.2. Subcutaneous route (SC)  
This route does not require the use of anaesthesia as well. It is performed on the 
dorsocaudal lateral parts of the animal back at the level of the hind limbs. The animal 
is immobilized with the help of a piece of cloth over his head, pinching the animals’ 
loin with the same hand and inserting the needle with the other hand parallel to the 
spine. This process can be carried out several times a day over several days. 
 
Table 3. Substance administered by SC injections. 
3.3. Intracerebroventricular route (ICV) 
It is used to deliver certain substances in the lateral ventricles of the rat’s brain. It 
is performed on a fully conscious animal and does not require the use of anaesthesia. 
Immobilizing the animal with a piece of cloth where the animal was gently pressed 
against the base of the cage to avoid excessive stress; the implanted cannula was 
opened by using scissors at the sealed end, a Hamilton syringe (Model 7001KH 25s, 
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Hamilton) is introduced and emptied once it is properly inserted. The needle is 
removed with extreme care by holding the cannula to prevent displacement of the 
insertion site. The same person repeats this procedure for several days that never 
exceeds 10 days of the implantation of the cannula. 
 
Table 4. Substance introduced by ICV administration. 
4. Non-surgical procedures 
4.1. Monitoring of food intake and body weight:  
Body weight and food intake values were collected by using a precision scale; both 
Animals and their food were weighed daily, always more or less at the same time in 
each experiment. In the case of group caging of animals, the mean food intake was 
calculated depending on the number of individuals of each box. 
4.2. Determination of body composition:   
Body composition analysis was done by using the magnetic resonance imaging 
techniques (Whole Body Composition Analyzer Echo-MRI 500 Echo-MRI, Houston, 
Texas, USA) both at the beginning and end of the experiments if possible; the data on 
the composition of fat mass, lean mass and water of each animal were obtained and 
analysed.  
4.3. Temperature measurements 
Body temperature was recorded with a rectal probe connected to digital 
thermometer (BAT-12 Microprobe-Thermometer; Physitemp). Skin temperature 
surrounding BAT was recorded with an infrared camera (B335; Compact- Infrared-
Thermal-Imaging-Camera; FLIR) and analysed with a specific software package 
(FLIR-Tools-Software; FLIR) 
5. Surgical procedures  
5.1.  ICV cannulation 
The cannulas used for this purpose consisted of a polyethylene tube (BD 
Intradermic® Polyethylene tubing (Non-Sterile), Becton Dickinson and Company, 
Materials and methods 
69 
 
Franklin Lakes, NJ, USA) (PE-20 in the case of rats) of 1.09 mm outer diameter, 0.38 
mm inner diameter. A bevel shaped cut is made on one end at an angle of 45 °. A cape 
was inserted at a length of 0.5 mm to 4 mm at the bevelled side for rats. The total 
length of the cannula is 3.5mm. The other end was sealed until the time of treatment. 
Once the animals were anesthetized correctly, skin incision on the head (in front of 
the ears) perpendicular to the sagittal suture of about 1.5 cm is made. Using a 
mosquito, skin flaps were removed for optimal exposure of the surgical field. 
Subsequently, the subcutaneous tissue of the skull was removed exposing the insertion 
between the sagittal suture and the coronal suture, i.e. the bregma. Bleeding was 
managed by pressing gauze for a few seconds until the cessation of the bleeding. After 
the correct location of the bregma, perforation was made in the skull (to the right or 
left side of the bregma) by using a surgical drill at a lateral distance of 1.5 mm from 
the sagittal suture and 0.9 mm posterior to bregma. After reducing the eventual 
bleeding with gauze, the bevelled end of the cannula is inserted into the hole parallel 
to the dorsal-ventral axis of the animal. Finally, the cannula was secured to the skull 
of the animal with cyanoacrylate adhesive (SuperGlue-3 Loctite). After cannulation, 
animals were caged individually and left to recover for a period of 3-4 days before 
proceeding to the injection. 
5.2.  Orchiectomy (ORX) 
This procedure is for males where the animals are properly anaesthetized, a scrotal 
approach was used. A small incision is made at the tip of the scrotum. The tunic is 
opened and the testis, cauda epididymis, vas deferens, and the spermatic blood vessels 
are exteriorized by applying a little pressure. The blood vessels and vas deferens are 
then ligated. The testis and epididymis including the fat tissue are then removed. The 
remaining tissue is returned to the sac and the procedure repeated for the other testis. 
The skin incision was then closed. Sham operated rats are handled through the same 
surgical procedures except for the removal of the gonads. The animals should be left 
for a period no less than 3 weeks before further experiments were carried out to verify 
the complete disappearance of the androgens produced by the testis. 
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5.3. Ovariectomy (OVX) 
The animals are properly anaesthetized to perform bilateral OVX. The mid-dorsal 
thoracolumbar region is clipped to remove hair and prepared for aseptic surgery. 
Ovaries are typically approached by two separate flank incisions. Animals are laid on 
their side, the skin is separated from the underlying muscle before incising the muscle, 
the location of the ovarian fat pad is confirmed, the ovary is gently pulled through the 
incision with a blunt forceps by grasping the fat pad surrounding it. A haemostat is 
placed at the boundary between the oviduct and uterus, a ligature placed just below 
the haemostat (next to the uterus) and a cut is made just above the haemostat. Once 
the ovary is removed, the haemostat is released and haemostasis is verified before 
letting go the uterus and allowing it to return to the abdomen. Muscle layer is closed; 
skin is closed with wound clips. The process is repeated for the other side. Sham 
operated rats are handled through the same surgical procedures except for the removal 
of the gonads. The animals should be left for a period no less than 2 weeks before 
further experiments were carried out to verify the complete disappearance of the 
estrogens produced by the ovaries. 
6. Tissue dissection and extraction 
After the end of each experimental procedure, the animals were sacrificed by 
cervical dislocation and subsequent beheading according to the rules and laws of 
animal experiments. Tissues were then removed and stored at -80 °C until processing 
and analysis. In cases of microdissection was needed, it was conducted under an 
optical magnifier of 20x. 
7. Experimental design 
7.1.  ICV administration of 1 or 5 nmol of E2  
The rats were ovariectomized after allowing them an adaptation period, two weeks 
later, ICV cannulas were introduced. The drug or vehicle were centrally administered 
for up to 7 days before the dark cycle. 
The rats were randomly assigned to one of four groups: 
1. OVX treated with E2 
2. OVX treated with vehicle 
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3. SHAM treated with E2 
4. SHAM treated with vehicle 
Rats were caged individually after the cannulation. Food intake, body weight and 
core temperature were daily monitored. At the last day, rats were sacrificed and the 
different tissues were collected and stored at - 80  
 
 
7.2.  ICV administration of 1 nmol E2 along with SC β3-AR-antagonist 
SR59230A 
The rats were ovariectomized after an adaptation period, two weeks later, ICV 
cannulas were implanted. The drug or the vehicle was centrally administered for up to 
5 days before the dark cycle. The rats were treated previously SC with the β3-AR-
antagonist SR59230A for 2 days before the ICV started. 
The rats were randomly assigned to one of four groups 
1. OVX treated with vehicle + SC SR59230A 
2. OVX treated with vehicle+ SC vehicle 
3. OVX treated with E2+ SC SR59230A 
4. OVX treated with E2+ SC vehicle 
Rats were caged individually after the cannulation. Food intake, body weight and 
core temperature were daily monitored. At the last day, rats were sacrificed and the 
different tissues were collected and stored at - 80  
 




7.3.  Influence of physiological levels of E2 modulation  
Half of the rats were ovariectomized after adaptation while the other half have 
been examined daily by the means of vaginal smear and a microscope to detect the 
phase of estrus. Rats from diestrus were included in the experiment. 
The rats were randomly assigned to one of two groups 
1. OVX rats 
2. Diestrus phase rats 
At the last day, rats were sacrificed and the different tissues were collected and 
stored at - 80. 
7.4. ICV administration of 100 nmol of DHT for 7 days 
The rats were orchidectomized, after 3 weeks, ICV cannulas were implanted. The 
drug or the vehicle were centrally administered for 7 days before the dark cycle. 
The rats were randomly assigned to one of four groups 
1. ORX treated with DHT 
2. ORX treated with vehicle 
3. SHAM treated with DHT 
4. SHAM treated with vehicle 
Rats were caged individually after the cannulation. Food intake, body weight and 
core temperature were daily monitored. At the last day, rats were sacrificed and the 
different tissues were collected and stored at - 80  
 
7.5.  ICV administration of 100 nmol of DHT for 7 days alone with SC β2-
AR-antagonist Butoxamine 
The rats were orchidectomized, three weeks later, ICV cannulas were implanted. 
The medicament or the vehicle were centrally administered for up to 7 days before the 
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dark cycle. The rats were treated previously SC with the β2-AR-antagonist 
Butoxamine for one day before the ICV starts. 
The rats were randomly assigned to four groups 
1. ORX treated with vehicle + SC Butoxamine 
2. ORX treated with vehicle+ SC vehicle 
3. ORX treated with E2+ SC Butoxamine 
4. ORX treated with E2+ SC vehicle 
Rats were caged individually after the cannulation. Food intake, body weight and 
core temperature were daily monitored. At the last day, rats were sacrificed and the 
different tissues were collected and stored at - 80  
 
 
8. Analytical techniques 
8.1. Protein extraction 
At the beginning of the extraction, a small portion of tissue was separated and the 
rest of the sample was re-frozen at -80 ° C. Throughout the extraction process, the 
samples were maintained at 0 ° C to prevent protein degradation. The separated tissue 
was then placed in a 2 ml eppendorf tube with safety (Safe-Lock Tubes 2.0 ml, 
Eppendorf, Hamburg, Germany), a certain volume of lysis buffer with protease 
inhibitor was added (Complete ™, Roche, Mannheim, Germany), depending on the 
tissue from which protein was extracted (between 200 μl and 1000 μl). Also depending 
on the type of analysis to be performed with the extracted proteins, the buffer varies 
between the enzyme activity analysis and quantitation of protein expression. Samples 
were then homogenized by a process of mechanical cell disintegration and breakage 
by a homogenizer (TissueLyser II, Qiagen, Germantown, MD, USA) for 2-3 minutes 
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at a frequency of about 30 Hz. Subsequently, they were centrifuged for 30 minutes at 
13,200 rpm and 4 ° C (in case of WAT and BAT, further centrifugation of about 10 
minutes was performed to further remove the excess of fat). The supernatant was 
removed into several aliquots and frozen at -80 °C until analysed. 
 
Table 5. Composition of the lysis buffer. 
8.2. Protein quantification 
To determine the protein concentration in aliquots obtained from the extraction 
(both for measuring its activity or expression). The aliquots were kept at 4 ° C on ice 
and the protein quantification was carried out by the colorimetric method of Bradford 
(Bradford, 1976) using the Bio-kit Rad Protein Assay (Protein Assay Dye Reagent, 
Bio-Rad, Hercules, CA, USA). To this end, we proceeded to dilute each sample by a 
factor of 1:26 in distilled H2O eppendorfs. In a 96 well plate, they were loaded in 
duplicate of 10 µl of each sample, and then 250μl of Bradford reagent diluted 1: 4 in 
distilled H2O at 37 °C. In addition, for each plate, a calibration curve was made by 
serial dilution of BSA (bovine Albumin Fraction V powder, Sigma-Aldrich, St. Louis, 
USA) with 7 duplicate points (0.03125, 0.0625, 0.125, 0.125, 0.25, 0.5, 0.7 and 1 mg / 
ml). Then in a plate reader (Multiskan Go Microplate Spectrophotometer, Thermo 
Scientific, Rockford, IL, USA) the plate was incubated for 5 min at 37 and 
colorimetry was measured at OD (optical density) in each well at a wavelength of λ = 
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595nm. Through extrapolation of the values of the calibration curve, protein 
concentration of each sample was determined. After determining the amount of 
protein from each sample at the required concentration for each assay (10 to 20 µg / 
16 µl) aliquots were prepared. 
8.3. Western blot 
8.3.1. Sample preparation 
Proteins are separated by electrophoresis in denaturing polyacrylamide gels (SDS-
PAGE, Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis). This 
technique is based on the separation of proteins by their molecular mass, based on 
their migration in an electric field, it is necessary to neutralize a number of 
characteristics of the proteins that would result in erroneous migration patterns and 
incorrect identifications. On the one hand, it is necessary to remove the quaternary 
structure of the protein in order to be able to migrate in the gel as possible in 
proportion to its size. On the other hand, since the protein will be subjected to an 
electric field, it is necessary to eliminate the intrinsic charge of the polypeptides, 
denaturing and granting them the same charge. For this, an aliquot of each sample was 
prepared, with the same concentration of total protein (10-20 mg) in lysis buffer with 
a protease inhibitor. Each sample also had the same ratio of 5x loading solution. This 
loading buffer provides the aliquot with elimination of quaternary protein structure (β-
mercaptoethanol, Sigma-Aldrich, St. Louis, USA), standardizes its electric charge in 
proportion to its length (SDS Sodium dodecyl sulphate, Sigma-Aldrich, St. Louis, 
USA), a higher density (glycerol, Sigma-Aldrich, St. Louis, USA). All this facilitates 
loading on the gel and further comprises a dye, for identifying the migration 
(bromophenol blue, MERK, Darmstadt, Germany). 
 
Table 6. Composition of the loading buffer. 




Electrophoresis was performed in a gel consisting of a three dimensional structure, 
in a network formed by the polymerization of acrylamide and bis-acrylamide (N, N-
methylenebisacrylamide). The polymerization process is catalysed by ammonium 
persulfate (APS) (Ammonium persulfate, Sigma-Aldrich, St. Louis, USA) and 
TEMED (N, N, N, N tetramethyletilenediamina, Sigma-Aldrich, St. Louis, USA). The 
concentration of acrylamide and bis-acrylamide (30% Acrylamide / Bis Solution 29: 
1, Bio-Rad, Hercules, CA, USA) in the gel determines the size of the pores of the 
three-dimensional network and the degree of migration of the proteins by size. The gel 
consists of two fractions, a concentrator fraction with 4% acrylamide / bis-acrylamide, 
wherein the loaded samples are grouped so that the separation of proteins from 
different samples occur simultaneously, and a separating fraction with 6%, 8% and 
10% depending on the size of the protein of interest. The gels were mounted on an 
electrophoresis kit (Mini-PROTEAN Tetra Cell, Bio-Rad, Hercules, CA, USA) and 
immersed in a running buffer 1x. (Composition of 5X running buffer: Glycine 72 g, 
15 g of Trizma base, 5 g SDS, distilled H2O to 1L). 
Before loading the samples on the gel they were vortexed and heated at 95 ° C for 
10 minutes and vortexed again. In each well 16 µl of gel sample was loaded. In one of 
the lanes, 5 µl of a molecular weight marker (Precision Plus Protein Standards-Dual 
Color, Bio-Rad, Hercules, CA, USA) were loaded. In each of the provided gels, 
samples of all experimental groups were loaded. After this, the samples were 
subjected to an electric field (constant voltage of 120V-140V and amperage of 180 
mA), connecting the electrophoresis kit to a power source (Power Pac HC High 
Current Power Supply, Bio-Rad, Hercules, CA, USA), which induced proteins 
migration to the cathode. Electrophoresis was stopped when the migration front 
reached a distance of approximately 0.5 cm from the end of the gel. 
8.3.3. Transfer 
After the electrophoresis, the proteins were transferred to a membrane to proceed 
with the analysis of expression of each protein. They were subjected to an electric 
field to mobilize the proteins to the membrane where they will be adsorbed allowing 
the incubations with different antibodies. The type of transfer that was used is called a 
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semi-dry type, where the membrane and the gel were placed one below the other and 
separated by absorbent paper and the plates, these plates create the voltage (Trans-
Blot Semi-Dry Transfer Cell, Bio-Rad). PVDF membranes were used (Immobilon-P 
Polivinylidene Fluoride membrane, Millipore), and cut with dimensions of 8,5x6,5 
cm, previously activated methanol over 4 min, 5 min in distilled H2O and 5 min in 
transfer buffer were used. 
 
Table 7. Composition of the different concentrations of the transfer buffer 
The transfer paper (Extra Thick Paper Blot, Bio-Rad) was soaked in transfer 
buffer, It is necessary for the passage of electric current necessary for the transfer. the 
gel and the membrane were placed between two pieces of blotting paper so that proper 
transfer electric current occur; any bubbles that might present1 between this were 
removed with a roller. The transfer was carried out for 1 hour and 40 minutes at a 
constant amperage of 250mA electrophoresis kit connecting to a power source (power 
Pac HC High Current Power Supply, Bio-Rad, Hercules, CA, USA). To verify the 
correct transfer membranes were stained with Ponceau Red (Ponceau S Red, Sigma-
Aldrich, St. Louis, USA) dye. To remove the dye, a couple of washes with wash 
buffer were applied. 
 
Table 8. Composition of the different concentrations of the separator gels. 
8.3.4. Immuno-detection of proteins  
After a proper transfer to the membrane, they were incubated at room temperature 
for 1h with blocking buffer (blocking buffer components: 3g BSA in wash buffer 
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100ml). Thus, the specific binding provided by the membrane in all areas where there 
was transferred protein was removed. Subsequently, the membrane was cut with 
reference to the molecular weight marker, so that one could detect different membrane 
proteins, thus, different proteins could be detected simultaneously. Each piece of 
membrane was incubated for 1h at room temperature or overnight at 4 ° C with 
primary antibody (depending on the antibody and its specific conditions) previously 
diluted in blocking buffer.  
 
Table 9. List of antibodies used and their dilution 
After the time of incubation with the primary antibody, it was removed and the 
excess was washed of by three washes each for 5 min with washing buffer at room 
temperature. Next, the membranes were incubated for 1 hour at room temperature 
with a secondary antibody conjugated with Horseradish Peroxidase capable of 
recognizing and specifically binding to the primary antibody used. 
 
Table 10. Composition of the different concentrations of washing buffer. 
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8.3.5. Developing and fixing the signal. 
The secondary antibody was removed and the excess is also washed off by three 
washes; to proceed to reveal the membrane by using 1 ml of the revealing substrate 
that detects Horseradish Peroxidase in proportions of 1: 1 (Pierce ECL Western 
Blotting Substrate, Cultek). Membranes were incubated for 2 min in the dark with this 
substrate. Once past the incubation time, the membranes were placed in a developer 
cassette (Hyper cassette, Amersham Biosciences, Little Chalfont, UK) and were 
waterproofed with the help of transparent paper. Then it was proceeded to be 
processed in a dark room intended for that purpose. Introducing a developing sheet 
(Fuji Medical X-Ray Film Super RX, Fujifilm Corporation, Tokyo, Japan) on the 
membranes and the cassette was closed; that was allowed to expose to the 
chemiluminescent signal for a few seconds/minute depending on the protein type. the 
film was then removed and immersed in a developer solution (1:10 dilution) (G150, 
Developer / Replenisher, Agfa-Gevaert Group, Dubendorf, Switzerland) until the 
desired signal is displayed at which the film is immersed in a fixative liquid (1: 5 
dilution) (G354, Manual fixing Bath, Agfa-Gevaert Group, Dubendorf, Switzerland) 
for a couple of minutes in order to fix the signal. Finally, the film is washed with 
running water and then dried. 
8.3.6. Quantification of the signal. 
Quantification of the signal is performed by measuring the optical density of each 
sample signal, from scanned images (resolution 400 dpi, CanoScan 9900F, Canon, 
Tokyo, Japan) of the auto radiographed films with computer software called ImageJ 
(ImageJ 1.40g, Wayne Rasband, NIH, USA). Each measurement of optical density is 
corrected by measuring the optical density of a signal adjacent to the sample region. 
8.4. RT-PCR 
8.4.1. RNA extraction. 
The whole process was performed while keeping the samples on ice in order to 
avoid degradation of RNA. A small piece of frozen samples was mechanically 
homogenized with 1000 µl of Trizol (TRIZOL Reagent; Invitrogen, Carlsbad, CA, 
USA) for 3 min (with the same system used in case of protein extraction). After 
homogenization, the samples were allowed to stand at room temp for about 5 minutes. 
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Then 1 ml of chloroform (Chloroform, Sigma-Aldrich, St Louis, USA) was added to 
each sample and shaken vigorously for several seconds with a subsequent rest period 
of about 5 minutes. Then they were centrifuged at 12000 rpm for 15 min at 4 ºc where 
they become clearly separated into two phases: an aqueous phase (containing RNA) 
and an organic phase (containing proteins and lipids). Between both the inter-phase 
(containing DNA). The aqueous phase is removed carefully into another tube and the 
organic phase is discarded. Thus the RNA is separated from the other cellular 
components. 
Once RNA is separated, 1 ml of isopropanol was added (2-propanol, Sigma-
Aldrich, St Louis, USA) to each sample, then vortexed and placed at -20 ° C for about 
10 minutes (thus enabling the RNA to precipitate). After that, the samples were 
centrifuged for 10 minutes at 12000 rpm at 4 ° C to concentrate the RNA in the 
background. Once the supernatant is removed, 1 ml of ethanol was added (Ethanol 
absolute PA, Applichem / Pancreac, Darmstadt, Germany) at 70% dilution in DEPC 
H2O followed by short stirring and centrifugation for 5 minutes at 12000 rpm at 4 ° C. 
To remove as much ethanol as possible, another centrifugation round for 1 minute at 
13500 rpm and 4 ° C, and then the supernatant was removed with a pipette. Finally, 
resuspension in H2O DEPC and heating at 60 ° C for 15 minutes. 
8.4.2. RNA quantification. 
Quantification of RNA in each sample by using a spectrophotometer set at two 
wavelengths: 260 and 280 nm. The absorbance at 260 nm provides the amount of 
nucleic acids while that of 280nm provides the amount of protein. The purity of the 
sample was determined by studying the ratio 260/280, oscillation between 1.4 and 1.8 
was considered acceptable. All samples were then aliquoted at a concentration of 
100ng / µl. 
8.4.3. Reverse transcription (RT). 
The reverse transcription reaction was conducted in a total volume of 30 µl (as 
shown in Table 11). One negative control (RT-ve) (30 µl of the reaction mixture 
except m-MLV, whose volume was replaced by H20 MilliQ) was prepared. Once the 
reaction mixtures were prepared, incubation in a thermal cycler for 50 min at 37° C, 
Materials and methods 
81 
 
15 minutes at 42 ° C, 5 min at 95° C. Finally, the samples were kept at 4 ° C or frozen 
-20 until use. 
Table 11. Components reverse transcription reaction 
8.4.4. Real Time PCR (TaqMan). 
TaqMan probes were used as detection system (Specific probes labelled with 
fluorophores: donor and acceptor). It is based on the transfer of fluorescence energy 
by FRET type resonance (Fluorescence Resonance Energy Transfer) between the two 
molecules. The fluorescence used to perform PCR was TAMRA, which has a 
maximal absorption of 560nm and a maximal emission of 580nm. The primers used 
were designed with Primer Express (Applied Biosystems, Foster City, CA, USA) 
program and checked by BLAST data base. The PCR reaction mixture used had a 
final reaction volume of 12 μl. 
 
Table 12. Components of the PCR reaction in real time 
In addition to the samples, a negative control was loaded (-RT), a blank and a 
standard curve for both the problem gene and the control or the constitutive 
expression gene; This was done in duplicate. The standard curve consisted of 6 points 
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made by serial dilution (1: 4) from a total volume of 30-40μl resulting from a mixture 
of different RT samples (2μl RT different products, but always the same treatment or 
tissue). The amplification conditions were 50 ° C (2min), 95 ° C (10 min), 95 (15sec) 
and 60 (1 min) for 40 cycles in a system of Real Time PCR (7300 Real Time PCR 
System, Applied Biosystems, Foster City, CA, USA). Values were expressed in 
relation to hypoxanthineguanine phosphoribosyl-transferase (HPRT) levels.  
 
Table 13. Primers and probes for real-time PCR analysis. 
 
9. Statistical analysis 
Data from all experiments were tested for normality (Kolmogorov-Smirnov (K-
S) test) and then statistically analysed by using software PASW 18 (SPSS, Inc, 
Chicago, IL, USA.) or GraphPad Instad (GraphPad Instad Software, v5, La Jolla, CA, 
USA). The degree of statistical significance was determined for the experiments that 
have only one variable by t-test and ANOVA while those with two or more variables 
by ANOVA followed by Bonferroni post-hoc test was used. Results are represented in 
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percentage by function of the control, by taking the average value (M) and standard 
error of the mean (SEM) (mean ± SEM). In experiments in which parameters were 
monitored such as feed intake and body mass, these raw data are represented without 
making any percent ratio comparison. All results with P <0.05 were considered 

































































1. Estrogens and energy balance 
The modulation of energy balance by estrogens has been extensively studied by 
our group throughout the last few years as part of the doctoral thesis of both Dr. 
Ricardo Lage and Dr. Pablo Blanco Martinez de Morentin (Lage, 2010; Martinez de 
Morentin, 2013). The ovariectomized rats, as an estrogen deficient animal model have 
been validated as a proper model for studying these effects. Our previous studies have 
reported interesting remarks about the anorexigenic effect of estradiol.  Estradiol 
induces weight loss an anorexia thus promoting a negative energy balance both 
(Figure 16).  
 
Figure 16. Effect of E2 treatment on energy balance. A- Energy balance plot of rats ICV 
treated with vehicle or E2. Error bars represent SEM; n=7-12 animals per experimental 
group. 
 
1.1.  Estradiol and BAT thermogenesis 
The adipose tissue plays an important role in the regulation of energy balance 
and homoeostasis, both WAT and BAT (Contreras et al., 2015; Trayhurn et al., 2006). 
The recent reports about BAT presence and function in adult humans (Ouellet et al., 




involvement of hormones, such as estrogens, in this response. WAT can also take on 
characteristics of BAT in a phenomena called browning (Contreras et al., 2015), 
notably the induction of UCP1 expression. BAT thermogenesis regulation is an 
intense topic of investigation as it has the potential to tilt the energy balance from 
storage to expenditure, a strategy that holds promise to combat the growing epidemic 
of obesity and metabolic syndrome. While the effects of centrally administered 
estradiol on energy balance have been extensively reported, their effect on BAT 
thermogenesis has not fully understood. In continuation of the previous studies of our 
group, we have started to investigate whether or not centrally administered estradiol 
affects the thermogenic activity. BAT thermogenesis was quantified by using 
thermographic imaging analysis (Martinez de Morentin, 2013; Martinez de Morentin 
et al., 2014; Martinez de Morentin et al., 2015; Martinez de Morentin et al., 2012; 
Seoane-Collazo et al., 2014). We realized that central ICV administration of 1 nmol of 
E2 induced a marked decrease in body weight, food intake, and an increase in core 
temperature (Figure 17A). The increase in body temperature was associated with 
elevated UCP1 protein levels in BAT (Figure 17C) and a significant rise in the 
temperature of the skin surrounding interscapular BAT (Figure 17D) indicating 
increased BAT thermogenesis. No changes in the mRNA expression of thermogenic 
markers, such as uncoupling protein-1 (UCP1), peroxisome-proliferator-activated 
receptor-gamma coactivator 1 alpha (PGC1α) and beta (PGC1β) was detected in WAT 
(Figure 17E). These effects were induced due to central action of estrogens as the 
circulating levels of estrogens remained at control level even at a higher dose of E2 
ICV treatment (Figure 17B) while SC administration of estradiol was found to 






Figure 17. Central effects of ICV E2 on energy balance and thermogenesis (A–E): A- 
Body weight change (left panel), daily food intake (middle panel), and core temperature 
(right panel); B- Plasma E2 levels of OVX rats SC and ICV treated with vehicle or E2. C- 
protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein 
(lower panel); D- infrared thermal images (left panel) and quantification of temperature of the 
skin surrounding interscapular BAT (right panel) E- mRNA profiles of browning markers in 
WAT of OVX rats treated SC with vehicle or E2. Error bars represent SEM; n = 7–12 





1.2. Modulation of the VMH AMPK-SNS-BAT axis by estradiol: 
The role of AMPK in the VMH has a well-established role in the regulation of 
BAT thermogenesis (Lopez et al., 2010b; Martinez de Morentin et al., 2014; Martinez 
de Morentin et al., 2015; Martinez de Morentin et al., 2012; Seoane-Collazo et al., 
2014). Thus, we continued to investigate the effect of centrally administered E2 via 
ICV route on the AMPK pathway in the VMH. The VMH-AMPK activity was found 
to be suppressed (Figure 18A) while no significant change was noticed in the ARC 
AMPK activity (Figure 18B) that was used as a control. 
 
 
Figure 18. The effect of ICV E2 on the hypothalamic AMPK pathway activity (A–B): 
A- western blot autoradiographic images (left panel) and VMH levels of proteins of the 
AMPK pathway (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol) B- 
western blot autoradiographic images (left panel) and ARC levels of proteins of the AMPK 
pathway (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol). Error bars 
represent SEM; n = 7–12 animals per experimental group. *, ** and ***p < 0.05, 0.01 and 
0.001 versus vehicle ICV. 
 
Next, we aimed to investigate the involvement of β3-adrenergic receptor (β3-
AR) in the control of BAT thermogenesis (Mund and Frishman, 2013). This was 




(Lopez et al., 2010b). We proceeded with central ICV administration of 1 nmol of E2 
to SC treated animals with either the β3-AR-antagonist SR59230A for 2 days or 
vehicle. The antagonist prevented the changes in body weight induced by estrogen 
without any effect on food intake (Figures 19A, 19B).  In keeping, we found that 
estrogen effects on core temperature (Fig 19C) and in UCP1 expression (Fig 19D) 
were mediated by activation of β3-adrenergic receptors. 
 
Figure 19. Effect of β3-adrenergic receptor blockade on the central E2 induced 
thermogenesis (A-D). A- Body weight change, B- daily food intake, C- core temperature, 
and D- western blot autoradiographic images of BAT UCP1 protein (left panel) and UCP1 
protein levels (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol), previously 
SC treated with the β3-AR-antagonist SR59230A for 2 days. Error bars represent SEM; n = 
7–12 animals per experimental group. * and ***p < 0.05 and 0.001 versus vehicle ICV or 
vehicle ICV vehicle SC; # and ##p < 0.05 and 0.01 versus E2 ICV vehicle SC. 
 
1.3. Modulation of the VMH AMPK-SNS-BAT Axis by the physiological 
Levels of E2 
The level of circulating estradiol is in a dynamic state; it fluctuates during the 




low level of E2 (figure 20A). We aimed to investigate whether or not the fluctuations 
in the physiological level of circulating E2 is accompanied by alterations in the 
modulation of the VMH AMPK- BAT axis. We used female rats at diestrus for this 
study where they expressed higher core temperature (Figure 20A) and UCP1 protein 
levels in BAT (Figure 20B) than OVX rats. The AMPK pathway activity in the VMH 
was inhibited (Figure 20C). Overall, this data indicate that high endogenous 
estrogenic tone inhibits AMPK function in the VMH and increased BAT thermogenic 
program. 
 
Figure 20. Effect of physiological levels of E2 on the VMH AMPK-SNS-BAT Axis 
(A–C). (A) Serum E2 levels (left panel) and core temperature (right panel), (B) protein levels 
(upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel), 
and (C) western blot autoradiographic images (left panel) and levels of proteins of AMPK 
pathway in the VMH (right panel) of diestrus cycled rats. Error bars represent SEM; n = 7–8 
animals per experimental group. *, **, and ***p < 0.05, 0.01, and 0.001 versus OVX, vehicle 
ICV, or GFP VMH. 
 
2. Androgens and energy balance 
The contribution of androgens to the modulation of energy balance at a central 
level remains elusive. In this part of our thesis, we have decided to study the effect of 
central administration of androgens on energy balance and BAT thermogenesis. 




Androgen deficiency was induced by bilateral orchidectomy of the animal models as 
described in the methods section of this thesis. Rats were left for at least three weeks 
before any experimental procedure to allow the complete elimination of androgens. 
The study used DHT as an androgen of choice so that the effect of aromatase enzyme 
can be neglected.   
2.1. Validation of orchidectomized rats as a model of study 
Our first approach toward this study was a thorough evaluation of the effects of 
androgen withdraw on the different metabolic parameters of orchidectomized rats in 
comparison with SHAM operated ones. 
 
 
Figure 21. Effect of orchidectomy on the different metabolic parameters (A-G): A- 
body weight change B- daily food intake (g) C- Core temperature (ºC) D- Adipose tissue 
weight: BAT (left panel) and subcutaneous inguinal WAT (right panel) (E-G) E- infrared 
thermal images  F- quantification of temperature of the skin surrounding interscapular BAT: 
maximal skin temperature (left panel) and average skin temperature (right panel) G- 
quantification of protein levels (upper panel) and auto-radiographic western blotting images 
of BAT UCP1 protein (lower panel). Error bars represent SEM. * p < 0.05 and ***<0.001 





We have observed that orchidectomized rats lost weight (figure 21A) with no 
significant change in food intake (figure 21B). The core temperature was significantly 
elevated (figure 21C) in orchidectomized rats compared to the sham operated rats that 
were associated with a significant rise in the temperature of the skin surrounding 
interscapular BAT at both the maximal temperature and average skin temperature 
(figure 21F). Although orchidectomized rats lost weight, they were shown to gain fat 
mass in the form of subcutaneous inguinal white adipose tissue but not BAT (figure 
21D). These effects were accompanied by a significant reduction in the ARC AMPK 
activity (Figure 22) suggesting that the central effect of androgen deficiency on energy 
balance may be mediated by AMPK in the ARC.  
 
 
Figure 22. Levels of the AMPK pathway proteins in the ARC (A-B): A- quantification 
of the different protein levels (right panel) and B- auto-radiographic western blotting images 
(left panel). Error bars represent SEM. * p < 0.05 and **<0.01 versus SHAM operated 
control. n=6-8 animals per experimental group. 
 
2.2. Central androgenic modulation of energy balance 
To continue, we started to study the effect of DHT replacement for 7 days on 
the food intake and body weight. We proceeded with ICV administration of a 100nM 
DHT compared to vehicle in both SHAM operated or the orchidectomized rats based 
on several pilot experiments with different doses of DHT. The fact that the dose 
needed in case of estrogens was much lower though both were introduced via the 
same route might be related to their distinct effects in the sexual dimorphism of 





Figure 23. Effect of central replacement with DHT on food intake and body weight 
(A-B): A-  body weight change (g) B-  cumulative food intake (g) Error bars represent SEM. 
*p < 0.05 **p < 0.01 ***<.001 vs. ICV SHAM Vehicle. n=6-12. 
 
Central replacement with DHT enhanced weight gaining in ORX animals with 
no significant change in the cumulative food intake (Figure 23A and 23B). 
Conversely, that corresponds to significant alterations in AMPK activity in the ARC 
(figure 24) after DHT treatment of ORX rats.  
 
Figure 24. Levels of the AMPK pathway proteins in the ARC(A-B): A- quantification 
of the different protein levels and B- auto-radiographic western blotting images. SV 
represents SHAM operated ICV vehicle, SD represents SHAM operated ICV DHT, OV 
represents orchidectomized ICV vehicle and OD represents orchidectomized DHT. Error bars 
represent SEM. * p < 0.05 and **<0.01 versus SHAM operated vehicle and # p < 0.05 versus 





Core temperature was reduced in ORX animals (Figure 25B). In addition, both 
ORX and ICV treatment with DHT in Sham animals led to an increase in average and 
Maximal skin temperature (Fig 25A). This reduction in body temperature was 
accompanied by a significant reduction in the maximal temperature of the skin 
surrounding the interscapular BAT (Figure 25A) compared to the orchidectomized 
treated with vehicle. The protein expression of the thermogenic marker UCP1 showed 
a similar pattern of changes to those seen in maximal skin temperature (Figure 25B 
and 25C).  
 
 
Figure 25. Effect of ICV DHT on BAT thermogenesis (A-C): (A) upper, infrared 
thermal images, lower, quantification of temperature of the skin surrounding interscapular 
BAT, (B) core temperature, (C) quantification of protein levels (upper panel) and auto-
radiographic western blotting images of BAT UCP1 protein (lower panel). SV represents 
SHAM operated ICV vehicle, SD represents SHAM operated ICV DHT, OV represents 
orchidectomized ICV vehicle and OD represents orchidectomized DHT. Error bars represent 
SEM. ∗p < 0.05 **<0.01 ***<0.001 vs. ICV SHAM Vehicle # p < 0.05 versus 
orchidectomized ICV vehicle. n=5-15.  
 
 
At VMH level, AMPK pathway activity was significantly increased (Figure 
26A) following administration of DHT; thus promoting androgens to a valid member 






Figure 26. Levels of the AMPK pathway proteins in the VMH nucleus (A-B): A- 
quantification of the different protein levels and B- auto-radiographic western blotting 
images. SV represents SHAM operated ICV vehicle, SD represents SHAM operated ICV 
DHT, OV represents orchidectomized ICV vehicle and OD represents orchidectomized DHT. 
Error bars represent SEM. * p < 0.05 and **<0.01 versus SHAM operated vehicle and # p < 
0.05, ##<0.01 and ###<0.001 versus orchidectomized ICV vehicle. n=6-8 animals per 
experimental group. 
 
2.3. 2.3. Androgens: central actions with peripheral consequences 
Androgens are known for their physiological importance in the development 
and increase of muscle mass as well as their reduction of fat level as revealed by other 
studies (Roth and Page, 2011), we continued to investigate whether or not these 
actions are mediated centrally. We proceeded with the ICV DHT for 7 days’ treatment 
and by using magnetic resonance imaging (MRI) to quantify the change in muscle and 






Figure 27. Effect of ICV DHT on fat and lean masse(A-D): (A) Body weight change, 
(B) Fat mass change, (C) lean mass change (D) BAT and subcutaneous inguinal WAT. Both 
B and C are based on studies realized by using magnetic resonance technique (MR). Error 
bars represent SEM. *p < 0.05, **<0.01 vs. ICV SHAM Vehicle while #<0.05 versus 
orchidectomized ICV vehicle. n= 6-15. 
 
The orchidectomized rats centrally replaced with DHT showed a significant 
increase in body weight (figure 27A) that was mostly due to a significant increase in 
lean mass (Figure 27B) but not fat mass (Figure 27C, 27D). This may suggest that the 
mode of action of DHT on lean mass, and particularly on muscle might be centrally 
induced in addition to the local effect on the muscle itself. On the other hand, the 
amount of subcutaneous inguinal fat was significantly higher than SHAM treated with 
vehicle but not significantly reduced with central DHT treatment. No significant 
change in BAT weight was noticed. We also investigated the effect of central DHT on 
AMPK signalling in muscle. Our data showed that the AMPK pathway activity in the 
gastrocnemius muscle (a fast-twitch muscle) was altered; pAMPK and pACC were 




indicate that central DHT inhibits AMPK in muscle. These data together suggested a 
potential role of central DHT in the modulation of the mammalian target of rapamycin 
(mTOR), a target for muscle protein synthesis (Figure 28) (Saha et al., 2010).  
 
Figure 28. Levels of the AMPK pathway proteins in the gastrocnemius muscle (A-B): 
A- quantification of the different protein levels and B- auto-radiographic western blotting 
images. SV represents SHAM operated ICV vehicle, SD represents SHAM operated ICV 
DHT, OV represents orchidectomized ICV vehicle and OD represents orchidectomized DHT. 
Error bars represent SEM. * p < 0.05 and **<0.01 versus SHAM operated vehicle and 
##<0.01 versus orchidectomized ICV vehicle. n=6-8 animals per experimental group. 
 
To further investigate whether or not this interesting change in muscle mass 
involved the activation of β2-adrenergic receptor (β2-AR; its stimulation increases 
muscle mass by promoting muscle protein synthesis (Sato et al., 2011)). 
Pharmacological blockade with the specific β2-AR antagonist butoxamine was used 
(Arai et al., 2013). We proceeded with central ICV administration of 100 nmol of 
DHT previously SC treated with butoxamine for 1 day. While central DHT increased 
weight gain as lean mass, SC butoxamine reversed this particular effect with no 
significant change in body weight, food intake, core temperature or fat mass (Figures 
29A, 29B, 29C, 29D and 29E). These data indicate that central DHT increases lean 






Figure 29. Effect of β2-adrenergic receptor blockade on fat and lean masses with ICV DHT 
treatment (A-E): (A) Body weight change, (B) cumulative food intake, (C) core temperature, 
(D) Fat mass change (%BW), and (E) lean mass change (%BW). Both D and E are based on 
studies realized by using magnetic resonance imaging (MRI). Error bars represent SEM. ∗p < 
0.05**<0.01 ***<0.001 vs. ICV vehicle SC vehicle while #<0.05 versus ICV DHT SC 
vehicle. n= 6-10. 
 
 Furthermore, to continue studying the different effects of DHT, we started to 
further investigate the de novo lipogenesis on some peripheral tissues such as BAT 
and liver.  
 
Figure 30. Levels of the AMPK pathway proteins in the gastrocnemius muscle (A-B): A- 
quantification of the different protein levels and B- auto-radiographic western blotting images 
(right panel). SV represents SHAM operated ICV vehicle, SD represents SHAM operated 
ICV DHT, OV represents orchidectomized ICV vehicle and OD represents orchidectomized 
DHT. Error bars represent SEM. *p < 0.05 versus SHAM operated vehicle. n=6-8 animals 




Our data in BAT showed a decline tendency in the lipogenic markers with 
pAMPK was significantly increased in DHT treated ORX rats compared to vehicle 
treated ones (Figure 30).  
 
Figure 31. Levels of the AMPK pathway proteins in the liver (A-B): A- quantification 
of the different protein levels and B- auto-radiographic western blotting images. SV 
represents SHAM operated ICV vehicle, SD represents SHAM operated ICV DHT, OV 
represents orchidectomized ICV vehicle and OD represents orchidectomized DHT. Error bars 
represent SEM. * p < 0.05 and **<0.01 versus SHAM operated vehicle and # p < 0.05 and 
##<0.01 versus orchidectomized ICV vehicle. n=6-8 animals per experimental group. 
 
In the liver, the overall effect of DHT ICV treatment was to promote de novo 
lipogenesis; reducing the levels of pAMPK / pACC and increasing FAS (Figure 31). 
In general, our results indicate that the central effect of DHT are tissue-specific and 






















































































   
The data of this thesis demonstrate the influence of gonadal hormones as 
relevant players in thermoregulation. Moreover, it has identified the hypothalamus as 
a site where sex steroids, both E2 and DHT, can act centrally to modulate BAT 
thermogenesis.  The first part of this study identifies a link between the effects of E2 
on hypothalamic AMPK and BAT thermogenesis. Specifically, we show that 
activation of BAT thermogenic program and subsequent energy expenditure depends 
on inactivation of VMH AMPK. Overall, these results further expand our knowledge 
on the hypothalamic effects of estrogens on energy homeostasis and offer a 
physiological mechanism, via the energy sensor AMPK, for the central actions of E2 
that is of relevance in linking the changes in energy balance and may also help to 
understand obesity-associated alterations in the gonadal axis. 
Conditions in which ovarian estrogens are lacking, such as OVX or 
menopause, are associated with hyperphagia and decreased caloric expenditure that 
results in a positive energy balance leading to obesity. Estrogen replacement reverts 
this phenotype both in women and female rodents (Carr, 2003; Finan et al., 2012; 
Gao and Horvath, 2008; Mauvais-Jarvis et al., 2013). Although some discrepancies 
can arise when comparing both models of estrogen insufficiency (OVX and 
menopause) since in the first instance, there is an abrupt decrease in ovarian function 
while in the second is a progressive fall. Noteworthy, data gleaned in recent years in 
genetic models have shown that some of the actions of estrogens on energy 
homeostasis are centrally mediated through activation of ERα in the main 
hypothalamic nuclei, such as the ARC and the VMH (Musatov et al., 2007; Xu et al., 
2011b). In addition, data obtained previously in our group (Martinez de Morentin, 
2013) showed that estrogens exert some of its effects on energy balance by 
influencing energy expenditure via hypothalamic AMPK. 
Recent literature indicates that hypothalamic AMPK pathway is a central 
regulator of energy homeostasis that acts by controlling both feeding and energy 
dissipation (Andrews et al., 2008; Lopez et al., 2010b; Martinez de Morentin et al., 
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2012; Minokoshi et al., 2004; Whittle et al., 2012). As expected, ICV administration 
of E2 promoted a state of negative energy balance, characterized by hypophagia, 
increased energy expenditure, and BAT thermogenesis, leading to marked weight 
loss. These effects are reversed by pharmacological blockage of β3-AR 
independently of feeding and appear to derive from VMH-specific actions of E2 so 
that the impact of E2 on BAT thermogenesis derives from its ability to modulate 
AMPK activity in the VMH. 
Overall, these data confirm that E2 modulates energy homeostasis in a brain 
site-specific fashion (Xu et al., 2011b) and uncover a molecular mechanism (i.e. 
modulation of AMPK, by which E2 specifically modulates BAT metabolism). In 
recent years, hypothalamic metabolic energy sensors, such as AMPK, have been 
suggested to play a major role in the regulation of energy homeostasis. Several 
metabolic hormones, such as leptin, ghrelin, insulin, and thyroid hormones (Andrews 
et al., 2008; Lopez et al., 2010b; Minokoshi et al., 2004), and more recently BMP8b 
(Whittle et al., 2012), have been shown to regulate energy balance acting through 
AMPK. Here, we provide evidence that E2, a hormone that markedly influences 
energy and metabolic homeostasis, acts on the same sensors to control both feeding 
and energy expenditure. Notably, the mechanisms described here for the thermogenic 
actions of E2 display considerable commonalities with those previously unveiled by 
our group for thyroid hormone and BMP8b (Lopez et al., 2010b; Whittle et al., 
2012). Thus, the VMH AMPK-SNS-BAT axis appears to act as a canonical central 
mechanism integrating central and peripheral regulation of energy stores.  
In this regard, our data points to AMPK in the VMH as a potential target for 
the treatment of obesity and other metabolic disorders associated with conditions of 
endocrine deregulation. The relevance of such a pharmacological target is 
emphasized by recent reports showing that nicotine-induced anorexia and weight loss 
is in part mediated by actions on AMPK-expressing neurons in the VMH to increase 
energy expenditure (Martinez de Morentin et al., 2012), which could be exploited as 
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a potential therapeutic strategy. In addition, DiMarchi, Tschop, and colleagues have 
recently reported an elegant approach based on the development of a combinatorial 
peptide of a GLP-1-estrogen conjugate for the treatment of obesity and metabolic 
syndrome (Finan et al., 2012). They demonstrated that selective activation of ERs in 
GLP-1-targeted tissues enhanced the benefits of both E2 and GLP-1 agonism on 
body weight, glucose homeostasis, and lipid metabolism. Considering that both GLP-
1 receptor and ERα are highly expressed in the VMH (Gu et al., 2013; Shughrue et 
al., 1997), this raises the possibility that the metabolic benefits of E2 and GLP-1 
agonism may be mediated by selective modulation of AMPK in the VMH. However, 
further investigations are needed to test such possibility. 
The reason for the sex differences in energy metabolism is not completely 
known; however, it may be related to sex steroids, from which, the effects of 
androgens are relatively unknown. Low testosterone levels were found associated 
with metabolic syndrome, diabetes and cardiovascular disease (Corona et al., 2011a; 
Corona et al., 2011b; Zitzmann, 2009). Although it is known that testosterone may 
act on the brain to reduce food intake and modulate energy expenditure (Mauvais-
Jarvis, 2011), the exact mechanisms underlying this action remains not fully 
understood. Our studies showed that the reductions in food intake and body weight 
are mediated through reduction in AMPK activity in the ARC following 
orchidectomy that was reversed with central DHT administration. Concurrently, 
Studies on guinea pigs showed that androgen-induced increases in energy intake 
were mediated via an AMPK activation in the POMC neurons of the ARC (Borgquist 
et al., 2015). 
Interestingly, we wondered about the androgenic effects on the 
aforementioned pathways as well as on BAT thermogenesis. Previously the effects of 
testosterone on energy balance were largely thought to be attributed to aromatization 
(Mauvais-Jarvis, 2011). The experimental evidence attributing the effect of androgen 
signalling to BAT activity remains a controversial matter. Androgen-receptor 
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knockout male mice develop delayed obesity as a consequence of decreased energy 
expenditure and displays a reduced expression of Ucp1 in BAT depots (Fan et al., 
2005b; Yanase et al., 2008). These findings suggesting the possibility of a 
stimulatory effect of androgens on BAT thermogenesis appears to be at odds with the 
observation that testosterone treatment of cultured brown adipocytes shows a reduced 
Ucp1 expression levels (Rodriguez et al., 2002) as well as with our data that showed 
that androgens reduces BAT thermogenesis. On the other hand, in vivo 
administration of with dehydroepiandrosterone (DHEA; an androgen precursor) and 
testosterone has been shown no change in BAT thermogenic activity in experiments 
using male rats (Abelenda et al., 1992; Tagliaferro et al., 1986). 
Interestingly, our data using DHT that cannot be aromatized contradicts the 
effect of aromatization as estrogen upregulates the thermogenic pathways. Although 
our experimental model using DHT in both sham and ORX rats allowed us to study 
the effects of DHT in the presence and absence of endogenous testosterone level, the 
ORX-model is not without some limitations worth to take into consideration. In 
addition to the removal of Leydig cells, ORX is also associated with the loss of 
Sertoli cells and therefore decline in all their synthesized hormone products notably 
inhibin and activins.  Therefore, the differences in the effects obtained with DHT-
treated sham and ORX animals could be due to: a) the presence of endogenous 
testosterone levels in sham animals allows greater activation of the AR as well as 
activation of the ER through previous aromatization; b) In addition to decreasing the 
testosterone levels, ORX animals exhibited a reduction in the peptide hormones 
secreted by the Sertoli cells which can on its own influence energy expenditure. 
Therefore, DHT administration can functional compensate the loss of Leydig cell 
exerted via the AR but not the other ones. We are fully aware of these limitations and 
of the need to further explore this issue in the future using other models with 
selective loss of Leydig cells or genetic suppression of aromatization. Nevertheless, 
our data offers new insights on the central effects of androgens on energy 
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expenditure and metabolism that cannot be attributed to aromatization. We further 
attempted to elucidate the mechanisms responsible for the androgenic effects of 
testosterone on BAT thermogenesis. Following the same hypothesis of the last study, 
we realized that AMPK pathway activity in the VMH is increased, and BAT 
thermogenesis is reduced. Our current data support the notion that androgens reduce 
core body temperature (Fitts et al., 2004). Thus, it appears that testosterone treatment 
can reduce energy expenditure via a reduction in heat production in males. 
The lack of androgen receptor in mice was associated with reduced lipolysis 
and developed obesity (Yanase et al., 2008), Low testosterone level was associated 
with an increase in body fat and abdominal obesity (Gapstur et al., 2002; Kapoor et 
al., 2005). Physiological replacement of testosterone produces improved both obesity 
and obesity-related disorders in both men and rats (Davis et al., 2012; Kapoor et al., 
2006). Testosterone is known as a highly potent direct anabolic agent to skeletal 
muscle. Androgens also enhance the development of myocyte from pluripotent stem 
cells while decreasing adipocyte development thus increasing muscle mass (Singh et 
al., 2003). However, our data showed that DHT ICV treatment promoted weight gain 
that was mainly in the form of lean mass indicate the presence of indirect and central 
regulatory mechanisms of muscle mass. The skeletal muscles comprise the most 
abundant tissue in the human body constituting 40–50% of body mass. Skeletal 
muscle protein has a rapid turnover, which is governed by the balance between the 
rates of protein synthesis and degradation. Physical training and anabolic hormones 
and medications boost muscle protein level. However, cachexia, sarcopenia and 
muscle inactivity decrease muscle protein level.  
The rate of protein synthesis is at least partially controlled by β2-adrenergic 
receptors in skeletal muscles in both anabolic and catabolic conditions. The β2 
subtype is the most abundant subtype in muscle (Kim et al., 1991; Williams et al., 
1984). Furthermore, β2-AR is denser in slow-twitch muscles than in fast-twitch 
muscles (Ryall et al., 2002; Ryall et al., 2004). However, the magnitude of anabolic 
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responses to β2-adrenergic agonists is higher in fast-twitch muscles than in slow-
twitch muscles (Burniston et al., 2006; Ryall et al., 2006; Sato et al., 2008, 2010). 
Several studies have shown that β2-adrenergic agonists administration induce muscle 
hypertrophy in many species (Kim and Sainz, 1992; Lynch and Ryall, 2008; Ryall 
and Lynch, 2008). Experiments using mice lacking  β2-AR demonstrate that β2-
adrenergic agonist-induced effects such as muscle hypertrophy are mediated via β2-
AR (Hinkle et al., 2002). β2-Adrenergic agonists promote muscle growth by 
increasing the rate of protein synthesis with or without changes in protein 
degradation (Kim and Sainz, 1992; Lynch and Ryall, 2008; Ryall and Lynch, 2008). 
Also, androgens enhance beta-adrenergic receptors expression so that it increases 
lipolysis and decreases fatty acid synthesis (De Pergola, 2000). Thus, we postulate 
that pharmacological blockage of β2-AR, the most prominent in skeletal muscle, 
would reverse the androgenic effects. Our data using β2-AR antagonist supports this 
hypothesis which in turn holds the central actions of androgens as a nominee leading 
to the possibility of finding effective treatments for cachexia and wasting in chronic 
disease. 
On the other hand, certain obstacles will face the development of any 
androgen based therapeutics and testosterone therapy mainly due to the debts 
surrounding their role in the development of prostate cancer. The relationship 
between testosterone and prostate cancer has been described as the “fuel for a fire” or 
the “food for a hungry tumour”.   Even though the biological effects of testosterone 
have been recognized throughout the recorded history of humankind, even before 
identification of the key biochemical element produced by the testis, there are still a 
lot of misconceptions and misleading evidence surrounding androgens. The 1849 
rooster castration and subsequent testes transplantation performed by Arnold 
Berthold was the first scientific experiment to linked the physiological and 
behavioural changes of castration to a substance secreted by the testes (Morales, 
2013). Later on, David and colleagues isolated testosterone in 1935 (Nieschlag, 
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2006) and synthesized later that year. The following period after it first became 
available; testosterone therapy was extensively practiced. In 1941, Huggins and 
Hodges reported that castration caused regression of metastatic prostate cancer, and 
testosterone injections activated prostate cancer (Huggins and Hodges, 1941). From 
that point on, the use of testosterone became rare owing to fear of causing prostate 
cancer in otherwise healthy individuals. 
Recently,  there has been a remarkable and steady growth in the use of 
testosterone therapy (Baillargeon et al., 2013), beginning in the early 1990s, where 
Morgentaler and colleagues (Morgentaler et al., 1996)  and Thompson and colleagues 
(Thompson et al., 2004) pointed to the indication that low testosterone may be a risk 
factor for prostate cancer, and not protective against prostate cancer and its 
progression (Morgentaler, 2011). Also, there is a completed lack of compelling 
evidence that high testosterone levels contribute to the development of prostate 
cancer (Rhoden and Morgentaler, 2004). An extensive review found that men with 
higher endogenous testosterone or who had undergone testosterone therapy were not 
at increased risk of prostate cancer (Endogenous et al., 2008). Supraphysiologic 
doses of testosterone for up to 9 months in healthy men failed to demonstrate a 
significant increase in prostate-specific antigen or prostate volume (Bhasin et al., 
2001; Cooper et al., 1998). The notion that “more testosterone is bad, less 
testosterone is good” was not necessarily true. Conversely, Studies from Prout and 
Brewer (Prout and Brewer, 1967) and Fowler and Whitmore (Fowler and Whitmore, 
1981) present an alternative to the Huggins and Hodges work. Both noted no 
evidence of progression in men with prostate cancer not treated by androgen 
deprivation or castration (Fowler and Whitmore, 1981; Prout and Brewer, 1967). 
In summary, we show that central E2 inactivates AMPK in the VMH, which 
increases SNS tone, upregulates BAT thermogenesis, and increases energy 
expenditure, leading to weight loss, while in case of DHT, this action was reversed. 
Thus, our data add more evidence to the fact that AMPK, specifically in the VMH, is 
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a canonical mechanism modulating energy dissipation via SNS activation of BAT. 
This observation provides insights into the physiological regulation of energy balance 
and its perturbation in sex steroids deficient states and suggests that the VMH 


































The results obtained from the different experiments of this study allow us to 
establish the following conclusions: 
 Sex steroids centrally regulate BAT thermogenesis via acting specifically in the 
VMH and their actions are mediated by alterations in AMPK activity at this level. 
This effect appears to be of physiological relevance since fluctuations in endogenous 
estrogen levels are sufficient to modulate the VMH AMPK- BAT axis. 
 The central action of estrogens may be of great value in the fight against obesity and 
its comorbidities.  
 Androgens can centrally promote an increase in lean mass and consequently can 
become a beneficial target for developing treatments against cachexia and wasting in 
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ACC Acetyl-CoA carboxylase  
ACSs Acyl-CoA synthetase  
AgRP Agouti related peptide  
AMA American Medical Association  
AMP Adenosine monophosphate 
AMPK AMP-activated protein kinase 
ANP  Atrial natriuretic peptide 
APS Ammonium persulfate  
AR Androgen receptor 
ARC Arcuate nucleus  
AREs Androgen response elements  
ArKO Aromatase enzyme KO  
ATP Adenosine triphosphate  
BAT  Brown adipose tissue  
BBB Blood–brain barrier 
BDNF Brain-derived neurotropic factor 
BMI Body mass index  
BNP  Brain natriuretic peptide 
CART Cocaine and amphetamine regulated transcript 
CB1 Cannabinoid receptor type 1 
CCK Cholecystokinin 
CHF Congestive heart failure 
CKD Chronic kidney disease  
CNS  Central nervous system 
CPT1 Carnitine-palmitoyl transferase 1  
CRH Corticotropin-releasing hormone 
DBD DNA-binding domain  
DHEA Dehydroepiandrosterone  
DHT  Dihydrotestosterone 
DMH Dorsomedial nucleus  
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DPN Diarylpropionitrile  
E1 Estrone  
E2 17β-estradiol 
E3 Estriol  
EE Energy expenditure 
ER Estrogen receptor 
ERE Estrogen response element  
ERRs Estrogen related receptors 
EST Tissue estrogen sulfotransferase  
FAS Fatty acid synthase  
FSH Follicle-stimulating hormone  
GHRH Growth hormone-releasing hormone  
GLP-1 Glucagon-like peptide-1  
GnRH Gonadotropin releasing hormone  
GPER G-protein-coupled estrogen receptor 
GPR30 G-protein coupled receptor 30 
GR Glucocorticoid receptor  
GSIS Glucose-stimulated insulin secretion 
HARKO Hepatocytes AR 
HAT Histone acetylation  
HDAC Histone deacetylation  
HFD High fat diet  
HPT Hypothalamic pituitary thyroid axis 
HPG Hypothalamic pituitary gonadal axis 
HSD17-β  17-β hydroxysteroid dehydrogenase  
HSD17-β3 17-β hydroxysteroid dehydrogenase type III 
HSPs Heat-shock proteins  
ICV Intracerebroventricular rout 
IP Intraperitoneal route  
KO knockout 
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LBD Ligand-binding domain  
LCFAs Long chain fatty acids  
LCFAs-CoA Long chain fatty acyl-CoA 
LepRb Leptin Receptor Long Isoform 
LH Luteinizing hormone 
LHA Lateral hypothalamus area 
M Average value 
MC3R Melanocortin receptor 3 
MC4R Melanocortin receptor 4 
MCD  Malonyl-CoA decarboxylase 
ME Median eminence  
mER Membrane estrogen receptor  
MR Mineralocorticoid receptor  
MRI Magnetic resonance imaging  
mTOR Mammalian target of rapamycin  
NARKO Neuronal specific ArKO  
NPY Neuropeptide Y  
NTS Nucleus tractus solitarius  
Ob-R Leptin receptor  
ORX Orchidectomized  
OVX Ovariectomized 
PGC1 α  Peroxisome-proliferator-activated receptor-gamma coactivator 1 alpha 
PGC1 β Peroxisome-proliferator-activated receptor-gamma coactivator 1 beta  
POA Preoptic area  
POMC Proopiomelanocortin  
PP Pancreatic polypeptide  
PPT Propylpyrazoletriol  
PR progesterone receptor  
PVH Paraventricular nucleus  
PYY Peptide YY 
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RMR Resting metabolic rate  
rRPa Rostral raphe pallidus  
RT-PCR Reverse transcription polymerase chain reaction 
SC Subcutaneous route  
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SEM Standard error of the mean 
SF1 Steroidogenic factor 1  
SHBG Sex hormone-binding globulin  
SNS Sympathetic nervous system 
StAR Steroidogenic acute regulatory protein  
T Testosterone  
T2D Type 2 diabetes 
TEMED  N, N, N, N tetramethyletilenediamina 
TF Transcription factors  
TG Triglycerides  
TRH Thyrotropin-releasing hormone 
UCP-1 Uncoupling protein-1  
VMH Ventromedial nucleus  
WAT White adipose tissue  
WHO World Health Organization  
α-MSH α-melanocyte stimulating hormone  
β2-AR  β2-adrenergic receptor  
β3-AR β3-adrenergic receptor  
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Appendix I 
Summary: 
Both living and the quality of life depends to great extent on the ability of an 
organism to maintain their internal environment and systems in a state of homeostasis. The 
homeostasis of energy balance is no exception; our body struggles to provide a stable balance 
between energy consumed and expended. Imbalance in any direction will result in its 
consequences and health issues. Obesity results from a chronic imbalance between energy 
consumed and expended; favouring energy consumption and causing overgrowth of the 
adipose tissue to a level that adversely affects the state of health (Sanchez-Gurmaches and 
Guertin, 2014b). Obesity is associated with some comorbidities including insulin resistance, 
type 2 diabetes (T2D), cardiovascular disease, cancer, a range of other disorders collectively 
known as the metabolic syndrome (van der Klaauw and Farooqi, 2015). The diseases 
following obesity not only affect the quality of patients’ life but also stands for a great sum of 
medical costs (Heindel et al., 2015) that is susceptible to further increase considering the 
level and pattern of obesity prevalence in both developed and developing countries (WHO, 
2014). Focusing on the factors behind obesity revealed that the changes in our environment, 
availability of intense energy highly palatable known as fast foods with less physical activity, 
as well as genetic predisposition are its main predisposing factors.  
On the other hand, Cachexia results from a long-standing imbalance between energy 
intake and expenditure where expanded energy exceeds dietary intake (Evans et al., 2008). It 
involves weight loss mainly in the form of muscle with or without loss of fat mass despite not 
actively trying (Evans et al., 2008).  Also, Cachexia cannot be entirely reversed by dietary 
supplementation. The main issues with cachexia are their negative effect on the quality of life 
that may result in higher mortality rates (Lok, 2015) among patients suffering from chronic 
illness including chronic obstructive pulmonary disease, chronic kidney disease, congestive 
heart failure, and cancer. Both obesity and cachexia are now considered a public health 
problem and the development of interventions to block or attenuate it would have notable 
therapeutic benefits considering the current lack of valuable cure to both syndromes.  
Energy balance homeostasis is a complex process that involves the interaction of all 
parts of our body at the different levels. The peripheral organs and tissues including the gut, 
white adipose tissue (WAT), gonads, muscles, and the thyroid gland continuously supply the 
CNS with signals about the metabolic and nutritional situation of the body (Flier, 2004; 
Fruhbeck and Gomez-Ambrosi, 2003; Lopez et al., 2007b; Medina-Gomez and Vidal-Puig, 
2005; Wren and Bloom, 2007). These signals might be hormonal such as cholecystokinin 
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(CCK), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1), leptin, ghrelin, 
adiponectin, resistin, and insulin, mechanical signals; gastric distension, chemical signals; 
ingested food components or even nerve signal; vagal afferent stimulation. The CNS then 
integrates these signals and initiates the proper response allowing efficient energy 
homeostasis; by modifying the expression of the main neuropeptides (Flier, 2004; Fruhbeck 
and Gomez-Ambrosi, 2003; Lopez et al., 2007b; Medina-Gomez and Vidal-Puig, 2005; Wren 
and Bloom, 2007). Neuronal circuits are directly or indirectly involved in the regulation of all 
physiological activities, of which, the hypothalamic circuits are considered the primary 
regulator of food intake and energy homeostasis (Dieguez et al., 2009; Plum et al., 2006; 
Schwartz et al., 2000). Primarily, only two hypothalamic nuclei were supposed to have a role 
in the regulation of feeding; the lateral hypothalamic area (LHA) representing the feeding 
center and the VMH representing the satiety center (Anand and Brobeck, 1951; Hetherington 
and Ranson, 1940). These remarks were based on the observations from lesions of the LHA 
reduced food intake and eventually lead to starvation and death while that of the VMH 
resulted in obesity. Despite our expanding understanding of the hypothalamic regulation of 
feeding, the first idea that anatomically defined hypothalamic areas regulate food intake has 
persisted.  
Among these nuclei, the arcuate nucleus (ARC) is considered the prime hypothalamic 
center for food intake control. The ARC contains two distinct neuronal populations involved 
in the integration of peripheral signals. One set of neurons expresses the orexigenic 
neuropeptides agouti-related protein (AgRP) and neuropeptide Y (NPY). The other ARC set 
of neurons expresses the anorexigenic products of proopiomelanocortin (POMC), the 
precursor of alpha-melanocyte-stimulating hormone (α-MSH), and the cocaine and 
amphetamine-regulated transcript (CART). The central melanocortin system whose main 
element is POMC consists of these two neuronal populations and the downstream target 
neurons expressing the melanocortin receptor 3 (MC3R) and the melanocortin receptor 4 
(MC4R). This system is vital for efficient sensing and integration of peripheral signals 
allowing the proper energy homeostatic mechanism (Butler, 2006; Lee and Wardlaw, 2007; 
Seeley et al., 2004; Xu et al., 2011a). When energy intake exceeds expenditure, the 
expression of orexigenic neuropeptides, such as AgRP and NPY diminishes, whereas the 
expression of anorexigenic neuropeptides, such as CART and POMC, rises. Opposite 
changes occur when energy expenditure exceeds intake. The two populations of neurons in 
the ARC broadly project within the CNS, to secondary hypothalamic nuclei such as the 
dorsomedial nucleus (DMH), The VMH, the LHA, and the paraventricular nucleus (PVH). 
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The PVH is also an integration site involved in energy homeostasis (Kim et al., 2000; Stanley 
et al., 1986). The LHA plays a critical role in mediating the orexigenic responses as the 
possess both orexin and melanin- concentrating hormone (MCH) neurons (de Lecea et al., 
1998; Ferno et al., 2015; Lopez et al., 2010a; Sakurai et al., 1998). The DMH is also a vital 
hypothalamic center for energy balance regulation; it is involved in both the regulation of 
appetite and thermoregulation (Chan et al., 1996; Chao et al., 2011; Kamegai et al., 1996). 
The VMH is also implicated in the regulation of energy balance; it plays a key role in the 
regulation of BAT thermogenesis (Lopez et al., 2010b; Martinez de Morentin et al., 2014; 
Martinez de Morentin et al., 2012; Seoane-Collazo et al., 2014; Whittle et al., 2012). 
Furthermore, the consumed energy is used in either resting metabolic rate (RMR; the 
amount of energy needed at rest to maintain the basic cellular metabolic activities), physical 
activity or thermoregulation. The brain controls these three categories of energy expenditure 
(Lopez et al., 2010b; Martinez de Morentin et al., 2014; Martinez de Morentin et al., 2012; 
Rui, 2013; Seoane-Collazo et al., 2014; Silva, 2003; Whittle et al., 2012). BAT is valuable for 
its role in adaptive thermogenesis (Cannon and Nedergaard, 2004; Contreras et al., 2015; 
Whittle et al., 2011). Functionally, WAT can be considered an energy store mainly in the 
form of triglycerides (TG) while BAT burns these TG to produce heat. For many years, BAT 
was known for its important role in small animals and human babies, but recently, BAT has 
been reported to not only present but also is functional in adult humans. Moreover, a 
phenomenon called the browning of WAT has been reported. It involves the appearance of a 
particular type adipocytes called beige, brite, or recruitable brown adipocytes in anatomically 
new locations corresponding to WAT but has a lesser capacity in vivo (Lee et al., 2014; Lidell 
et al., 2013; Sharp et al., 2012). The sympathetic nervous system (SNS) is essential to 
activate BAT thermogenesis as reflected by a high density of nerve endings in the tissue 
(Cannon and Nedergaard, 2004; Cao et al., 2001). Norepinephrine activates an adrenergic 
receptor that generates signals to enhance thermogenesis and stimulate intracellular lipolysis 
(Cannon and Nedergaard, 2004). The thermogenesis of BAT is associated with the presence 
of a mitochondrial membrane protein called the uncoupling protein-1 (UCP-1), or 
thermogenin, that is present in the inner mitochondrial membrane of BAT adipocytes. This 
protein enhances thermogenesis through uncoupling between respiratory chain complexes 
and the adenosine triphosphate (ATP) production promoting free protons movement into the 
mitochondrial matrix, thus generating heat instead of ATP (Cannon and Nedergaard, 2004; 
Garlid et al., 2000; Jaburek et al., 2001; Whittle et al., 2011; Zingaretti et al., 2009).  
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Many hypothalamic nuclei are associated with the regulation of thermogenesis as 
evidenced by using retrograde viral tracing in the BAT area of rats that revealed the potential 
connection with the preoptic area (POA), PVH, DMH, and LHA (Cano et al., 2003; Oldfield 
et al., 2002). The POA is considered the classical center responsible for thermoregulation 
(Boulant, 2000). Recently, the crosstalk between VMH and BAT has evolved where 
stereotaxic specific administration of glutamate, hydroxybutyrate, norepinephrine, serotonin, 
and tryptophan into VMH activated BAT (Amir, 1990; Hugie et al., 1992; Sakaguchi et al., 
1988; Sakaguchi and Bray, 1989; Yoshimatsu et al., 1993). More recently, genetic evidence 
using VMH- SF-1 knockout mice has also supported the role of the VMH in the modulation 
of BAT thermogenesis (Jo, 2012; Kim et al., 2011).  
BAT expresses estrogen, progesterone, and testosterone receptors (Rodriguez-Cuenca 
et al., 2007). Many studies support the difference in the effect of sex steroids on BAT 
thermogenesis between genders both in human and animals. In humans, computed 
tomography scans showed that active BAT is more abundantly present in women than men 
that may result from their greater sensitivity to cold (Au-Yong et al., 2009; Cypess et al., 
2009; McArdle et al., 1984; Perkins et al., 2013). In small animals, females appear to have 
larger BAT, larger mitochondria, and increased UCP1 activity than males (Justo et al., 2005; 
Quevedo et al., 1998; Rodriguez-Cuenca et al., 2002; Rodriguez et al., 2001). Regarding the 
metabolic and thermogenic activity of BAT, the lipid droplets in BAT adipocytes become 
more abundant and larger with estradiol and progesterone compared to testosterone, 
suggesting higher cellular metabolic capacity (Rodriguez et al., 2002). Also, BAT 
thermogenesis is downregulated during pregnancy and lactation to preserve energy (Frontera 
et al., 2005). VMH silencing of the ERα resulted in weight gain, visceral adiposity, increased 
food intake, and a decrease in BAT thermogenesis (Xu et al., 2011b).  
Recently a vast bulk of data has demonstrated that basic cellular metabolic pathways 
play a significant role in the regulation of whole-body energy homeostasis.  Of which, the 
hypothalamic modulation of lipid metabolism plays an important role in feeding control. The 
pharmacologic and genetic targeting of principal enzymes from these pathways, such as 
AMPK, acetyl-CoA carboxylase (ACC), carnitine palmitoyltransferase 1c (CPT1c), fatty acid 
synthase (FAS), and malonyl-CoA decarboxylase (MCD), has a primary effect on food intake 
and body weight.  Malonyl-CoA is not only an intermediary product in the biosynthesis of 
fatty acids but also a critical regulator of the balance between de novo lipogenesis and fatty 
acid oxidation (Yue and Lam, 2012). Levels of malonyl-CoA depend on the equilibrium 
between the activities of several enzymes such as ACC, FAS, and MCD (Dieguez et al., 
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2009). The activities of ACC and MCD are regulated by phosphorylation of AMPK (Dowell 
et al., 2005; Lage et al., 2008; Lopez et al., 2007a; Ruderman et al., 2003).  
The AMPK is the downstream element of a kinase cascade that serves as a sensor of 
cellular energy levels. Current data show that hypothalamic AMPK has a pivotal role in the 
regulation of the whole body energy balance including the integration of peripheral and 
central signals to elicit allostatic changes in energy homeostasis. AMPK is profoundly 
expressed in several key hypothalamic nuclei, such as the ARC, PVH, VMH and the LHA 
(Minokoshi et al., 2004).  Modulation of AMPK in the hypothalamus is a part of the adaptive 
changes noted during the physiological regulation of feeding. Fasting enhances AMPK 
activity in many hypothalamic regions while refeeding suppresses it (Andersson et al., 2004; 
Minokoshi et al., 2004). Consistent with this evidence, activation of hypothalamic AMPK 
increases both feeding and body weight while its inhibition favours hypophagia and weight 
loss (Andersson et al., 2004; Lopez et al., 2008; Minokoshi et al., 2004). The impact of 
AMPK in the VMH emerged as a part of the mechanisms that regulates BAT activity (Lopez 
et al., 2010b; Martinez de Morentin et al., 2014; Martinez de Morentin et al., 2012; Seoane-
Collazo et al., 2014; Whittle et al., 2012). There is an inverse correlation between VMH 
AMPK activity and BAT thermogenesis.  
Sex steroid hormones (estrogens, progestins, and androgens) are not only participating 
in normal reproductive function but also, regulate many physiological functions. They are 
either secreted by the gonads or to a lesser extent synthesized locally in extragonadal tissues. 
The hypothalamic-pituitary-gonadal axis (HPG axis) points to the relation between the 
hypothalamus, pituitary gland, and gonads. Sex steroid hormones are secreted in response to 
gonadotropins released from the anterior pituitary induced by gonadotropin-releasing 
hormone (GnRH) from the hypothalamus. It is evident that gender, reproduction, and energy 
metabolism are interrelated (Hill et al., 2008). Any severe changes in the energy balance such 
as obesity, anorexia, and cachexia have a negative influence on fertility (Cardozo et al., 2012; 
Du Plessis et al., 2010; Sermondade et al., 2012). On the other hand, lacking estrogen or 
androgen predispose to obesity and its associated comorbidities (Carr, 2003; Zitzmann, 
2009). Sex hormones, particularly estradiol, have a clear impact on the regulation of energy 
balance. For example, estrogen deficiency resulted in higher energy intake and increased 
body weight in ovariectomized rodents and post-menopausal women that can be reversed by 
treatment with steroid hormones.   
In humans, gender is associated with differences in energy metabolism due to the 
actions of sex steroid hormones linked to distinct body fat distribution and energy substrate 
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utilization patterns (Varlamov et al., 2014). Data gleaned in recent years have uncovered the 
central effects of estrogens at the hypothalamus in energy balance through the energy sensor 
AMPK. The main objective of this work was to further evaluate the central effect of sex 
steroids (estrogens and androgens) on energy balance with a particular focus on the 
regulation of BAT thermogenesis. To this end, we have designed different experiments to 
further investigate these effects. We have used various animal models including adult male 
and female Sprague–Dawley rats (Rattus norvegicus) weighting around 200 – 250 g of 
approximately (8-11 weeks old) from the Animalario General of the University of Santiago 
de Compostela. All animals were maintained on a 12-hour light (0800–2000 h), 12-hour dark 
cycle in a temperature/humidity-controlled rooms. The animals were allowed free access to 
standard laboratory chow pellets and tap water. The experiments were conducted in 
agreement with the International Law on Animal Experimentation and were accepted by the 
USC Local Ethical Committee and the Ministry of Science and Innovation of Spain (Project 
ID:15005AE/10/FUN/FISIO2/MLP2 and 15010/14/006). The rats were either bilaterally 
ovariectomized (OVX), orchidectomized (ORX) or sham-operated. Central treatments 
(estradiol and DHT) were carried out two or 3 weeks respectively after surgery to ensure a 
total washout of endogenous sex steroid hormones. Peripheral treatments (butoxamine and 
SR59230A) were carried out 1 or 2 days respectively before the central treatments.  
Food intake and body weight recorded daily along every treatment schedule; 
cumulative and daily average of food intake (g/24 hour), as well as body weight change since 
the beginning of each treatment, were calculated. Body temperature was recorded by using a 
rectal probe connected to a digital thermometer (BAT-12 Microprobe- Thermometer; 
Physitemp). Skin temperature of the area surrounding BAT was recorded with an infrared 
camera (B335; Compact- Infrared-Thermal-Imaging-Camera; FLIR) and subsequently 
analysed by using a specific software package (FLIR-Tools-Software; FLIR). Body 
composition analysis was done by using the magnetic resonance imaging techniques (Whole 
Body Composition Analyzer Echo-MRI 500 Echo-MRI, Houston, Texas, USA) both at the 
beginning and end of the experiments. 
Chronic intracerebroventricular (ICV) cannulas were implanted under ketamine-
xylazine anaesthesia (50 mg/kg, IP) with the correct positioning in the lateral ventricle. The 
animals were individually caged and used for experiments 4 days after cannulation. During 
the postoperative recovery period the rats became accustomed to the handling procedure 
under non-stressful conditions. For the estradiol experiments; 17 β-estradiol (1 or 5 nmol 
dissolved in 5 μL of dimethylsulfoxide (DMSO); Sigma) was used for the ICV treatments in 
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a mixture of DMSO: saline (1:10) during 3-7 days.  For the dihydrotestosterone experiments; 
(DHT; 100 nmol dissolved in 5 μL of DMSO; Sigma) central ICV administration continued 
for 7 days. For the β3-AR specific antagonist (SR59230A; 3 mg/kg/day; Tocris Bioscience, 
Bristol) was subcutaneously administrated, starting two days before the ICV E2 injections. 
For the β2-AR specific antagonist (Butoxamine; 1 mg/kg/day; Sigma) was administrated 
subcutaneously, starting one day before the ICV DHT injections. After the end of each 
experimental procedure, the animals were scarified by cervical dislocation and subsequent 
beheading according to the rules and laws of animal experiments. Tissues were then removed 
and stored at -80 °C until processing and analysis. In cases of microdissection was needed, it 
was conducted under an optical magnifier of 20x. 
In case of western blotting, following the extraction and quantification, protein lysates 
from the whole hypothalamus, or a particular nucleus; VMH, or ARC, liver, BAT or muscle 
were subjected to SDS-PAGE, electro-transferred on a polyvinyl difluoride membrane, and 
probed with the primary antibodies such as (ACCα, AMPKα1, AMPKα2 (Millipore), FAS 
(Becton, Dickinson), pACC-Ser79, pAMPK-Thr172 (Cell Signaling), UCP1 (Abcam), β-
actin, α-tubulin (Sigma) followed by incubation with the secondary antibody conjugated with 
Horseradish Peroxidase capable of recognizing and specifically binding to the primary 
antibody used. The membranes then proceed to the process of developing and fixing the 
signal, the membrane is subjected to 1 ml of the revealing substrate that detects Horseradish 
Peroxidase (Pierce ECL Western Blotting Substrate, Cultek) that is followed by introducing a 
developing sheet (Fuji Medical X-Ray Film Super RX, Fujifilm Corporation, Tokyo, Japan) 
on the membranes waterproofed in a cassette at the dark room and allowing it to expose to 
the chemiluminescent signal. the film was then removed and immersed in a developer 
solution (G150, Developer/Replenisher, Agfa-Gevaert Group, Dubendorf, Switzerland) until 
the desired signal is displayed at which the film is immersed in a fixative liquid (G354, 
Manual fixing Bath, Agfa-Gevaert Group, Dubendorf, Switzerland) for a couple of minutes. 
Finally, the film is washed with running water and then dried. Quantification of the signal is 
performed by measuring the optical density of each sample signal, from scanned images 
(resolution 400 dpi, CanoScan 9900F, Canon, Tokyo, Japan) of the auto radiographed films 
with computer software called ImageJ (ImageJ 1.40g, Wayne Rasband, NIH, USA).  
Data from all experiments were statistically analysed using software PASW 18 
(SPSS, Inc.). The degree of statistical significance in the experiments that have only one 
variable was determined by t-test and ANOVA while those with two or more variables by 
ANOVA followed by Bonferroni post-hoc test was used. Results are represented in 
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percentage by function of the control, by taking the average value (M) and the standard error 
of the mean (SEM) (mean ± SEM). All results with P <0.05 were considered significant; very 
significant at P <0.01 and highly significant at P <0.001.  
Our data showed that both estrogens and androgens play a major role in the 
modulation of energy balance through central actions. We show that central action of E2 
inhibits AMPK in the VMH, leading to activation of thermogenesis in BAT in a feeding-
independent manner. Notably, fluctuations in E2 levels during estrus cycle also modulate this 
integrated physiological network. On the other hand, DHT-treated rats had an increase weight 
gain with no change in energy intake. We also showed a lowered body temperature as well as 
skin area around the interscapular area that are associated with increased AMPK activity in 
the VMH and decreased BAT thermogenesis. We also showed that the lean mass of the DHT-
treated animals was increased, action that was reversed by using β2-AR specific antagonist 
suggesting a potential role for centrally acting androgens in controlling muscle mass. overall, 
we have demonstrated that central E2 inactivates AMPK in the VMH which increases SNS 
tone, upregulates BAT thermogenesis, and increases energy expenditure, leading to weight 
loss, while in case of DHT, this action was reversed. Thus, our data add more evidence to the 
fact that AMPK, specifically in the VMH, is a canonical mechanism modulating energy 
dissipation via SNS activation of BAT. This observation provides insights into the 
physiological regulation of energy balance and its perturbation in sex steroids deficient states 
and suggests that the VMH AMPK-SNS-BAT axis may be a potential therapeutic target for 





     
Appendix II 
Sumario: 
Tanto la vida como la calidad de vida dependen en gran medida de la capacidad de un 
organismo para mantener sus sistemas y el medio interno en un estado de homeostasis. La 
homeostasis del balance energético no es una excepción; nuestro cuerpo lucha para 
proporcionar un equilibrio estable entre la energía consumida y gastada. El desequilibrio en 
cualquier dirección resultará en consecuencias como problemas de salud. La obesidad es el 
resultado de un desequilibrio crónico entre la energía consumida y gastada; favoreciendo el 
consumo de energía y causando el crecimiento excesivo del tejido adiposo a un nivel que 
afecta negativamente el estado de salud (Sanchez-Gurmaches and Guertin, 2014b). La 
obesidad se asocia con algunas comorbilidades como la resistencia a la insulina, diabetes tipo 
2, enfermedades cardiovasculares, cáncer, y una variedad de otros trastornos conocidos 
colectivamente como el síndrome metabólico (van der Klaauw and Farooqi, 2015). Las 
enfermedades asociadas a la obesidad no sólo afectan a la calidad de vida de los pacientes 
sino también representan una gran suma en gastos médicos (Heindel et al., 2015) que es 
susceptible de aumento teniendo en cuenta el nivel y el patrón de prevalencia de obesidad en 
los países desarrollados y los países en vías de desarrollo (WHO, 2014). Centrándonos en los 
factores que subyacen a la obesidad los cambios en nuestro entorno, la alta disponibilidad 
energía altamente digerible conocida como comidas rápidas, una menor actividad física, así 
como la predisposición genética son los principales factores predisponentes. 
Por otro lado, la caquexia resulta de un desequilibrio de muchos años entre la ingesta 
de energía y el gasto; donde la energía expandida supera la ingesta alimentaria (Evans et al., 
2008). Se trata de una pérdida de peso principalmente en forma de músculo con o sin pérdida 
de la masa grasa (Evans et al., 2008).Además, la caquexia no se puede revertir totalmente con 
suplementos dietéticos. El principal problema de la  caquexia es su efecto negativo sobre la 
calidad de vida que resulta en mayores tasas de mortalidad (Lok, 2015) entre pacientes que 
sufren de enfermedades crónicas incluyendo enfermedad pulmonar obstructiva crónica, 
enfermedad renal crónica, insuficiencia cardíaca congestiva y cáncer. Tanto la Obesidad 
como la caquexia se consideran un problema de salud pública y el desarrollo de 
intervenciones para bloquear o atenuarlo tendrían notables beneficios terapéuticos teniendo 
en cuenta la falta actual de curación para ambos síndromes.  
La homeostasis del balance energético es un proceso complejo que involucra la 
interacción de todas las partes de nuestro cuerpo en los diferentes niveles. Los órganos y 
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tejidos periféricos incluyendo el intestino, el tejido adiposo blanco (WAT), gónadas, los 
músculos, y la glándula tiroides suministran continuamente al CNS señales sobre el 
metabolismo y la situación nutricional del cuerpo (Flier, 2004; Fruhbeck and Gomez-
Ambrosi, 2003; Lopez et al., 2007b; Medina-Gomez and Vidal-Puig, 2005; Wren and Bloom, 
2007). Estas señales pueden ser hormonales; tales como la colecistoquinina (Cholecystokinin; 
CCK), el péptido YY (Peptide YY; PYY) y el péptido similar al glucagón -1 (Glucagon-like 
peptide-1; GLP-1), la leptina, la grelina, la adiponectina, la resistina, y la insulina; señales 
mecánicas; como la distensión gástrica, señales químicas; como los componentes de los 
alimentos ingeridos o incluso señales nerviosas; como la estimulación del nervio vago 
aferente. El CNS entonces integra estas señales e inicia la respuesta apropiada que permite la 
homeostasis energética eficiente mediante la modificación de la expresión de los principales 
neuropéptidos (Flier, 2004; Fruhbeck and Gomez-Ambrosi, 2003; Lopez et al., 2007b; 
Medina-Gomez and Vidal-Puig, 2005; Wren and Bloom, 2007). Los circuitos neuronales 
están involucrados directa o indirectamente en la regulación de todas las actividades 
fisiológicas, de los cuales, los circuitos hipotalámicos se consideran el principal regulador de 
la ingesta de alimentos y la homeostasis energética (Dieguez et al., 2009; Plum et al., 2006; 
Schwartz et al., 2000). 
 En un primer momento, se supuso que sólo dos núcleos hipotalámicos tenian un 
papel en la regulación de la alimentación; el área lateral del hipotálamo (Lateral 
hypothalamic area; LHA) que representa el centro de alimentación y el núcleo hipotalámico 
ventromedial (Ventromedial hypothalamus; VMH) que representa el centro de la saciedad 
(Anand and Brobeck, 1951; Hetherington and Ranson, 1940). Estas observaciones se basaron 
en la reducción de la ingesta de alimentos producida por las las lesiones del LHA y que 
eventualmente podían conducir a la inanición y la muerte, mientras que las lesiones del VMH 
daban lugar a obesidad. A pesar de que nuestra comprensión de la regulación hipotalámica de 
la alimentación ha crecido, la primera idea en la que áreas hipotalámicas anatómicamente 
definidaregulan la ingesta de alimentos persistió. Entre estos núcleos, el núcleo arcuato 
(Arcuate nucleus; ARC) es considerado el centro hipotalámico principal para el control de la 
ingesta de alimentos. El ARC contiene dos poblaciones neuronales distintas implicadas en la 
integración de señales periféricas. Un conjunto de neuronas expresa los neuropéptidos 
orexigénicos: proteína relacionada con agouti (Agouti-related protein; AgRP) y el 
neuropéptido Y (Neuropeptide Y; NPY). El otro conjunto de neuronas expresa los productos 
anorexígenicos:  proopiomelanocortina (Proopiomelanocortine; POMC) y el precursor de la 
hormona alfa-estimulante de los melanocitos (α-Melanocyte-stimulating hormone; α-MSH), 
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así como el trancrito regulado por cocaína y anfetamina (Cocaine and amphetamine regulated 
transcript; CART). El sistema de melanocortina central, cuyo elemento principal es POMC, 
se compone de estas dos poblaciones neuronales y las neuronas corriente abajo que expresan 
el receptor de melanocortina 3 (Melanocortin receptor 3; MC3R) y el receptor de 
melanocortina 4 (Melanocortin receptor 4; MC4R). Este sistema es vital para la detección e 
integración de las señales periféricas que permiten el adecuado mecanismo de la homeostasis 
energética(Butler, 2006; Lee and Wardlaw, 2007; Seeley et al., 2004; Xu et al., 2011a). 
Cuando la ingesta de energía excede el gasto, la expresión de neuropéptidos orexigénicos, 
como AgRP y NPY disminuye, mientras que la expresión de neuropéptidos anorexígenos, 
como CART y POMC, se eleva. Cambios opuestos se producen cuando el gasto de energía 
excede la ingesta. Las dos poblaciones de neuronas en el ARC proyectan ampliamente dentro 
del CNS a los núcleos hipotalámicos secundarios, tales como el núcleo dorsomedial 
(Dorsomedial hypothalamus; DMH), el VMH, el LHA, y el     núcleo paraventricular 
(Paraventricular neucleus; PVH). El PVH también es un sitio de integración que participa en 
la homeostasis energética (Kim et al., 2000; Stanley et al., 1986). El LHA tiene un papel 
crítico en la mediación de las respuestas orexigénicas y está formado por neuronas que 
expresan orexina y hormona concentradora de melanina (Melanin-concentrating hormone; 
MCH) (de Lecea et al., 1998; Ferno et al., 2015; Lopez et al., 2010a; Sakurai et al., 1998). El 
DMH es también un centro hipotalámico de vital importancia para la regulación del balance 
energético que participa tanto en la regulación del apetito como en la termorregulación  
(Chan et al., 1996; Chao et al., 2011; Kamegai et al., 1996). El VMH también está implicado 
en la regulación del balance energético; desempeñando un papel clave en la regulación de la 
termogénesis del BAT (Lopez et al., 2010b; Martinez de Morentin et al., 2014; Martinez de 
Morentin et al., 2012; Seoane-Collazo et al., 2014; Whittle et al., 2012). 
La energía consumida se utiliza en la tasa metabólica en reposo (Resting metabolic 
rate; RMR; la cantidad de energía necesaria en reposo para mantener las actividades 
metabólicas celulares básicas), la actividad física y la termorregulación. El cerebro controla 
estas tres categorías de gasto de energía (Lopez et al., 2010b; Martinez de Morentin et al., 
2014; Martinez de Morentin et al., 2012; Rui, 2013; Seoane-Collazo et al., 2014; Silva, 2003; 
Whittle et al., 2012). El BAT es valioso por su papel en la termogénesis adaptativa (Cannon 
and Nedergaard, 2004; Contreras et al., 2015; Whittle et al., 2011). Funcionalmente, el WAT 
puede considerarse un acumulador de energía, principalmente en forma de triglicéridos 
(Triglycerides; TG), mientras que el BAT quema estos TG para producir calor. Durante 
muchos años, el BAT era conocido por su importante papel en animales pequeños y bebés 
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humanos, pero recientemente, se ha observado que el BAT no sólo está presente, sino que 
también es funcional en humanos adultos. Por otra parte, se ha descrito un fenómeno llamado 
pardeamiento del WAT que consiste en la aparición de un tipo particular de adipocitos 
denominados beige, brite, o adipocitos marrones que se reclutan en ubicaciones 
anatómicamente correspondientes a WAT (Lee et al., 2014; Lidell et al., 2013; Sharp et al., 
2012). El sistema nervioso simpático (Sympathatic nervous system; SNS) es esencial para 
activar la termogénesis en el BAT como se refleja por la alta densidad de terminaciones 
nerviosas en este tejido (Cannon and Nedergaard, 2004; Cao et al., 2001). La norepinefrina 
activa un receptor adrenérgico que genera señales para mejorar la termogénesis y estimular la 
lipólisis intracelular (Cannon and Nedergaard, 2004). La termogénesis del BAT se asocia con 
la presencia de una proteína de membrana mitocondrial llamada proteína desacopladora-1 
(Uncoupling protein-1; UCP-1), o thermogenina, que está presente en la membrana interna de 
la mitocondria de los adipocitos del BAT. Esta proteína aumenta la termogénesis a través del 
desacoplamiento entre los complejos de la cadena respiratoria y la producción de trifosfato de 
adenosina (Adenosine triphosphate; ATP) que promueven el movimiento protones libres en 
la matriz mitocondrial, generando calor en vez de ATP (Cannon and Nedergaard, 2004; 
Garlid et al., 2000; Jaburek et al., 2001; Whittle et al., 2011; Zingaretti et al., 2009). Muchos 
núcleos hipotalámicos están asociados con la regulación de la termogénesis como se 
evidencia mediante el uso de rastreo viral retrógrado de la zona BAT de ratas que revela una 
posible relación con el área preóptica (Preoptic área; POA), el PVH, el DMH, y el LHA 
(Cano et al., 2003; Oldfield et al., 2002). El POA es considerado el centro clásico responsable 
de la termorregulación (Boulant, 2000). Recientemente, la relación entre VMH y BAT ha ha 
sido estudiada viendose que la administración estereotáxica específica de glutamato, 
hidroxibutirato, norepinefrina, serotonina y triptófano en VMH activa el BAT (Amir, 1990; 
Hugie et al., 1992; Sakaguchi et al., 1988; Sakaguchi and Bray, 1989; Yoshimatsu et al., 
1993). Más recientemente, evidencias genéticas también han apoyado el papel del VMH en la 
modulación de la termogénesis del BAT utilizando ratones VMH-SF-1 knockout (Jo, 2012; 
Kim et al., 2011). 
El BAT expresa receptores de estrógeno, progesterona y testosterona (Rodriguez-
Cuenca et al., 2007). Muchos estudios apoyan la diferencia en el efecto de los esteroides 
sexuales sobre la termogénesis en el BAT entre géneros, tanto en seres humanos y animales. 
En los humanos, la tomografía computarizada mostró que el BAT activo está más 
abundantemente presente en las mujeres que en los hombres, algo que puede ser resultado de 
su mayor sensibilidad al frío (Au-Yong et al., 2009; Cypess et al., 2009; McArdle et al., 
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1984; Perkins et al., 2013). En los animales pequeños, las hembras parecen tener un BAT 
más grande, mitocondrias más grandes, y una actividad de UCP-1 mayor que los machos 
(Justo et al., 2005; Quevedo et al., 1998; Rodriguez-Cuenca et al., 2002; Rodriguez et al., 
2001). En cuanto a la actividad metabólica y termogénica del BAT, las gotas de lípidos en los 
adipocitos marrones se vuelven más abundantes y grandes con estradiol y progesterona en 
comparación con la testosterona, lo que sugiere una mayor capacidad metabólica celular 
(Rodriguez et al., 2002). Además, la termogénesis en BAT es regulada a la baja durante el 
embarazo y la lactancia para conservar la energía (Frontera et al., 2005). El silenciamiento en 
VMH del ERα resultó en un aumento de peso, de la adiposidad visceral y en un aumento de 
la ingesta de alimentos y una disminución de la termogénesis en BAT (Xu et al., 2011b). 
Recientemente, un gran número de datos ha demostrado que las vías metabólicas 
celulares básicas juegan un papel importante en la regulación de la homeostasis energética de 
todo el cuerpo. De los cuales, la modulación del metabolismo de lípidos hipotálamico 
desempeña un papel importante en el control de alimentación. Las intervenciones 
farmacológicas y genéticas dirigidas a las principales enzimas de estas vías, como la proteína 
activada por AMP quinasa (AMP-activated protein kinase, AMPK), acetil-CoA carboxilasa 
(Acetyl-CoA carboxylase; ACC), carnitina palmitoiltransferasa 1c (Carnitine-palmitoyl 
transferase 1c; CPT1c), ácido graso sintetasa (Fatty acid synthase; FAS), y malonil-CoA 
descarboxilasa (Malonyl-CoA decarboxylase; MCD), tienen un efecto capital en la ingesta de 
alimentos y el peso corporal. El malonil-CoA no es sólo un producto intermedio en la 
biosíntesis de ácidos grasos, sino también un regulador crítico del equilibrio entre la 
lipogénesis de novo y la oxidación de ácidos grasos (Yue and Lam, 2012). Los niveles de 
malonil-CoA dependen del equilibrio entre las actividades de varias enzimas tales como 
ACC, FAS, y MCD (Dieguez et al., 2009). Las actividades del ACC y MCD están reguladas 
por la fosforilación de AMPK (Dowell et al., 2005; Lage et al., 2008; Lopez et al., 2007a; 
Ruderman et al., 2003). 
AMPK es un elemento de la cascada de quinasas que sirve como un sensor de los 
niveles de energía celular. Los datos actuales muestran que la AMPK hipotalámica tiene un 
papel fundamental en la regulación del balance energético de todo el cuerpo, incluyendo la 
integración de las señales periféricas y centrales para provocar cambios alostáticos en la 
homeostasis energética. AMPK se expresa profundamente en varios núcleos hipotalámicos 
clave, como el ARC, el PVH, el VMH y el LHA (Minokoshi et al., 2004).  
La modulación de AMPK en el hipotálamo es una parte de los cambios de adaptación 
observados durante la regulación fisiológica de la alimentación. El ayuno aumenta la 
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actividad de AMPK en muchas regiones del hipotálamo, mientras que la alimentación la 
inhibe (Andersson et al., 2004; Minokoshi et al., 2004). En consonancia con esta evidencia, la 
activación de AMPK en el hipotálamo aumenta tanto la ingesta de alimentos como el peso 
corporal, mientras que su inhibición favorece la hipofagia y la pérdida de peso (Andersson et 
al., 2004; Lopez et al., 2008; Minokoshi et al., 2004). El impacto de AMPK en el VMH surge 
como parte de los mecanismos que regulan la actividad del BAT (Lopez et al., 2010b; 
Martinez de Morentin et al., 2014; Martinez de Morentin et al., 2012; Seoane-Collazo et al., 
2014; Whittle et al., 2012). Existe una correlación inversa entre la actividad de la AMPK en 
el VMH y la termogénesis en BAT. 
Las hormonas sexuales esteroideas (estrógenos, progestágenos y andrógenos) no sólo 
participan en la función reproductiva normal, sino que también, regulan muchas funciones 
fisiológicas. Estas son secretadas por las gónadas y en menor medida por los tejidos extra 
gonadales de manera local. El eje hipotálamo-hipofisario-gonadal (Hypothalamic pituitary 
gonadal axis; eje HPG) apunta la relación entre el hipotálamo, la glándula pituitaria y las 
gónadas. Las hormonas sexuales esteroideas se secretan en respuesta a las gonadotropinas 
liberadas en la pituitaria anterior que es inducida por la hormona liberadora de gonadotropina 
(Gonadotropin releasing hormone; GnRH) desde el hipotálamo. Es evidente que el género, la 
reproducción y el metabolismo energético están relacionados entre sí (Hill et al., 2008). 
Todos los cambios severos en el balance energético, tales como la obesidad, la anorexia, y la 
caquexia tienen una influencia negativa en la fertilidad (Cardozo et al., 2012; Du Plessis et 
al., 2010; Sermondade et al., 2012). Por otra parte, la falta de estrógenos o andrógenos 
predisponen a la obesidad y sus comorbilidades asociadas (Carr, 2003; Zitzmann, 2009). Las 
hormonas sexuales, particularmente el estradiol, tienen un impacto claro en la regulación del 
balance energético. Por ejemplo, la deficiencia de estrógeno resulta en un mayor consumo de 
energía y en un aumento de peso corporal en roedores ovariectomizados y mujeres 
postmenopáusicas que puede ser revertida por el tratamiento con hormonas esteroideas. 
En los seres humanos, el género se asocia con diferencias en el metabolismo 
energético debido a las acciones de las hormonas esteroides sexuales sobre la distinta 
distribución de la grasa corporal y sobre los patrones de utilización de sustratos energéticos 
(Varlamov et al., 2014). Los datos recogidos en los últimos años han descubierto los efectos 
centrales de los estrógenos sobre el hipotálamo en el balance energético a través del sensor 
energético AMPK. El principal objetivo de este trabajo fue profundizar en el estudio del 
efecto central de los esteroides sexuales (estrógenos y andrógenos) en el balance energético 
con un enfoque particular: la regulación de la termogénesis en BAT. Con este fin, hemos 
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diseñado experimentos diferentes para investigar más a fondo estos efectos. Hemos utilizado 
diversos modelos animales, incluyendo rata macho adulto y ratas hembras de la cepa 
Sprague-Dawley (Rattus norvegicus) con una masa corporal de 200 - 250 g aproximadamente 
(8-11 semanas) del Animalario General de la Universidad de Santiago de Compostela. Todos 
los animales se mantuvieron con ciclos de luz-oscuridad de 12 horas (8:00 horas-20:00 horas) 
en habitaciones con control de temperatura/humedad. A los animales se les permitió un 
acceso libre a dieta estándar y agua. Los experimentos se llevaron a cabo de acuerdo con el 
Derecho Internacional sobre la experimentación con animales y fueron aceptados por el 
Comité Ético local de la USC y el Ministerio de Ciencia e Innovación de España (Proyecto 
ID: 15005AE / 10 / FUN / FISIO2 / MLP2 y 15010/14/006). Las ratas fueron 
ovariectomizadas bilateralmente (Ovarectomized; OVX), castradas (Orchidectomized; ORX) 
o simuladamente operadasmente. Los tratamientos centrales (estradiol y DHT) se llevaron a 
cabo 2 o 3 semanas después de la cirugía, respectivamente, para garantizar una depleción 
total de los esteroides endógenos. Los tratamientos periféricos (butoxamine y SR59230A) se 
llevaron a cabo 1 o 2 días antes de los tratamientos centrales, respectivamente 
La ingesta de alimentos y el peso corporal se registró diariamente a lo largo de cada 
programa de tratamiento; calculándose de manera acumulativa y como promedio diario la 
ingesta de alimentos (g / 24 horas) y el cambio de peso corporal desde el inicio de cada 
tratamiento. La temperatura corporal se registró mediante el uso de una sonda rectal 
conectada a un termómetro digital (BAT-12 Microprobe- Thermometer; Physitemp). La 
temperatura de la piel de la zona que rodea al BAT fue grabado con una cámara de infrarrojos 
(B335; Compact- Infrared-Thermal-Imaging-Camera; FLIR) y posteriormente las imágenes 
se analizaron mediante un software específico (FLIR-Tools-Software; FLIR). El análisis de la 
composición corporal se llevó a cabo mediante el uso de las técnicas de imagen por 
resonancia magnética (Whole Body Composition Analyzer Echo-MRI 500 Echo-MRI, 
Houston, Texas, USA), tanto al comienzo como al final de los experimentos. 
Las cánulas intracerebroventriculares (Intracerebroventricular; ICV) se implantaron 
bajo anestesia de ketamina-xilazina (50 mg / kg, IP) siendo posicionadas en el ventrículo 
lateral. Los animales fueron alojados en jaulas individuales y se utilizaron para los 
experimentos 4 días después de la canulación. Durante el período de recuperación 
postoperatorio, las ratas se acostumbraron al procedimiento de manejo en condiciones no 
estresantes. Para los experimentos de estradiol; el 17 β-estradiol (1 o 5 nmol, disuelto en 5 μl 
de dimetilsulfóxido (DMSO); Sigma) se utilizó para los tratamientos ICV en una mezcla de 
DMSO: solución salina (1:10) durante 3-7 días. Para los experimentos de DHT (DHT; 100 
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nmol disueltos en 5 μl de DMSO, Sigma) la administración ICV continuó durante 7 días. El 
antagonista específico β3-AR se administró por vía subcutánea, empezando dos días antes de 
las inyecciones ICV de E2 (SR59230A; Tocris Bioscience, Bristol; 3 mg / kg / día). Para el 
antagonista específico β2-AR (butoxamine; 1 mg / kg / día; Sigma) se administró por vía 
subcutánea, comenzando un día antes de las inyecciones ICV de DHT. Después del final de 
cada procedimiento experimental, los animales fueron sacrificados por dislocación cervical y 
posterior decapitación de acuerdo con las normas y leyes de experimentación animal. Los 
tejidos fueron retirados y almacenados a -80 °C hasta su procesamiento y análisis. En los 
casos en los que era necesario microdisección, se llevó a cabo bajo una lupa óptica de 20x. 
En caso del western blot, después de la extracción y cuantificación, los lisados de 
proteínas de todo el hipotálamo, o un núcleo en particular; VMH, o ARC, hígado, BAT o 
músculo se sometieron a una SDS-PAGE, se electro-transferieron a una membrana de 
difluoruro de polivinilo, y se incubaron con los anticuerpos primarios (ACCα, AMPKα1, 
AMPKα2 (Millipore), FAS (Becton, Dickinson), PACC -Ser79, pAMPK-Thr172 (Cell 
Signaling), UCP1 (Abcam), β-actina, α-tubulina (Sigma), seguido de una incubación con el 
anticuerpo secundario conjugado con peroxidasa de rábano capaz de reconocer y unirse 
específicamente al anticuerpo primario utilizado. Luego las membranas se sometieron al 
proceso de revelado y a la fijación de la señal, para esto la membrana se somete a 1 ml del 
sustrato revelador que detecta la peroxidasa de rábano (Pierce ECL Western Blotting 
Substrate, Cultek) a continuación se introdujouna hoja reveladora (Fuji Medical X-Ray Film 
Super RX, Fujifilm Corporation, Tokyo, Japan) en un casete junto con las membranas 
impermeabilizadas en el cuarto oscuro que permite su exposición a la señal 
quimioluminiscentre. Después se retiró y se sumergió en una solución de revelado (G150, 
Developer / Replenisher, Agfa-Gevaert Group, Dubendorf, Switzerland) hasta que aparece la 
señal deseada y después se sumerge en un líquido fijador (G354, Manual fixing Bath, Agfa-
Gevaert Group, Dubendorf, Switzerland) durante un par de minutos. Por último, la película se 
lava con agua corriente y después se seca. La cuantificación de la señal se realiza mediante la 
medición de la densidad óptica de cada señal de la muestra, a partir de imágenes escaneadas 
(resolución de 400 dpi, CanoScan 9900F, Canon, Tokio, Japón) de las películas 
autoradiográficascon un software de ordenador llamado ImageJ (ImageJ 1.40g, Wayne 
Rasband, NIH, USA). 
Los datos de todos los experimentos se analizaron estadísticamente utilizando el 
software SPSS 18 (SPSS, Inc.). El grado de significación estadística en los experimentos que 
tienen sólo una variable se determinó mediante la T-test y ANOVA mientras que aquellos 
Appendixes 
165 
     
con dos o más variables se utilizó ANOVA seguido por la prueba de Bonferroni post hoc. 
Los resultados se representan en porcentaje en función del control, tomando el valor medio 
(M) y el error estándar de la media (Standard error mean; SEM) (media ± SEM). Todos los 
resultados con P <0,05 se consideraron significativos; muy significativas a P <0,01 y 
altamente significativas a P <0,001. 
Nuestros datos muestran que tanto los estrógenos como los andrógenos juegan un 
papel importante en la modulación del balance energético a través de acciones centrales. Se 
demuestra que la acción central de E2 inhibe la AMPK en el VMH, lo que lleva a la 
activación de la termogénesis en el BAT de manera independiente a la ingesta. En particular, 
las fluctuaciones en los niveles de E2 durante el ciclo estral también modulan esta red 
fisiológica. Por otra parte, las ratas tratadas con DHT tuvieron un aumento de peso aumento 
sin ningún cambio en la ingesta de energía. También se puso de manifiesto una bajada de la 
temperatura corporal, así como en el área de la piel alrededor de la zona interescapular que se 
asoció con una mayor actividad de la AMPK en el VMH y una disminución en la 
termogénesis del BAT. También se puso de manifiesto un incremento en la masa magra de 
los animales tratados con DHT, acción que fue revertida por el uso de un antagonista 
específico β2-AR lo que sugiere un posible papel de la acción central de los andrógenos en el 
control de la masa muscular. En general, hemos demostrado que el E2 inactiva AMPK en el 
VMH lo cual aumenta el tono del SNS, regulando al alza la termogénesis del BAT, y 
aumentando el gasto energético, dando lugar a la pérdida de peso, mientras que en caso de 
DHT, esta acción es inversa. Por lo tanto, nuestros datos añaden más evidencias sobre el 
hecho de que AMPK, específicamente en el VMH, es un mecanismo canónico en la 
modulación de la disipación de energía mediante la activación del BAT a través del SNS. 
Esta observación proporciona información detallada sobre la regulación fisiológica de los 
esteroides sexuales sobre el balance energético y sus perturbaciones en los estados 
carenciales sugiriendo que el eje VMH AMPK-SNS-BAT pueden ser una posible diana 
terapéutica para el tratamiento de la obesidad. 
 
 
     
 
 
 
 
